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The prevalence of clinical E. coli isolates showing an AmpC phenotype with reduced 
susceptibility to cephalosporins is increasing worldwide. In E. coli, which contains the wild-
type gene, hyperexpression is related to mutations in the promoter or in the attenuator regions. 
The most frequently described mutations change the promoter to resemble the E. coli 
consensus promoter or weaken the attenuator.  
 





generation cephalosporins, isolated in Norway from 2003 through 2007, was characterised by 
sequencing their ampC gene control and gene coding region. 51 isolates were shown to have 
alterations in the ampC gene control region, while four isolates showed no alterations in the 
gene control region. Seven isolates were identified carrying an IS-element. Further studies of 
these by isoelectric focusing (IEF), real-time qRT-PCR (qRT-PCR), pulsed-field gel 
electrophoresis (PFGE), and multi locus sequence typing (MLST) revealed that they 
hyperexpressed AmpC enzymes and four of them were clonally related to each other. Further 
investigations of the four strains without promoter alterations characterising their gene coding 
region showed that all had unique mutations. IEF confirmed their production of AmpC 
enzymes, while qRT-PCR revealed that they did not hyperexpress these proteins. MLST 
studies identified two strains associated with the same STC complex. The cloning experiment 
did not give us any clear answers to why the four isolates without promoter mutations express 
















Antimicrobial or antibacterial agents have derived their names from the term antibiotic. This 
term refers to natural metabolic products of fungi, actinomycetes and bacteria killing or 
inhibiting growth of microorganisms. Production of antibiotics is associated with natural soil 
microorganisms using the products in competition of space and nutrients with other 
microorganism. Sir Alexander Fleming was the first one to discover the bactericidal 
mechanism of penicillin in 1928, over 80 years ago. The observation of a mould inhibiting the 
growth of Staphylococcus aureus on a contaminated agar plate happened by chance. The 
mould was identified as a Penicillum notatum and Fleming gave the inhibitory substance the 
name penicillin [1]. Dr Howard W Florey and his colleagues in England were the first who 
managed to produce and purify the substance so it could be used for treatment purposes in 
1941 [2]. From 1945 and up to 1980 numerous of new classes of antimicrobials were 
discovered with an increasing rate. In the 1980s and 1990s only already known classes were 
improved, and the search for new agents is still ongoing today. The process of finding new 
effective agents has an average time line of 10 years. Random screening of soil 
microorganisms was the technique used, but this method is more and more replaced by a 
rational design program [3].  
Antimicrobial agents are either semi-synthetic or synthetic. Semi-synthetic agents are derived 
from natural products being chemically modified to enhance the efficacy. Synthetic agents 
like sulfonamides and quinolones are produced entirely from chemicals in laboratories [3].   
Antibacterial agents can be classified in three different ways; by chemical structure, by target 
site, or according to whether they are bactericidal or bacteriostatic. Classification by the 
bactericidal or bacteriostatic activity can be vague, because some antibacterial agents have 
bactericidal effect against one bacterium, but only a bacteriostatic effect against the other. 
Characterisation by the chemical structure is useless alone because of the diversity among 
agents. Classification by target site is more convenient because it helps in understanding the 




to a greater or lesser extent so that the agents won’t affect or be toxic to the patient infected. 
The five major mechanisms for actions are (i) inhibition of cell wall synthesis, (ii) inhibition 
of the cytoplamsmic membrane, (iii) inhibition of protein synthesis, (iv) inhibition of nucleic 
acid synthesis and (v) inhibition of folic acid synthesis [3]. 
 
Table 1.1.  Classification of antimicrobials by target site 
Target site Antimicrobials 
 
Penicillins 






  Bacitracin 
  Inhibition of cytoplasmic  Polymyxins 













  Tetracylines 
  Interference of nucleic  Quinolones 
acid synthesis Nitroimidazoles 
  Rifampicin 
  Inhibition of folic acid synthesis Sulphonamides 











In 1941 when the first penicillin was taken into use in therapy the optimism that it could kill 
any bacterial infection was huge. This optimism regarding the new super-drug was soon 
shattered, as reports on resistant bacteria in hospitals arose shortly after the introduction. 
Resistance occurred mainly in the hospital acquired infections. Infections acquired in the 
community were unaffected. Studies during 1950 and 1960 reported that multidrug resistance 
could be transferred to susceptible recipient cells [4, 5]. As new antimicrobial agents were 
discovered, and taken into use, the bacteria responded by manifesting various forms of 
resistance. Over the years the use of antimicrobial agents increased and the resistance 
mechanisms utilised by pathogenic bacteria also increased in level and complexity [6]. 
Bacteria are still developing new enhanced mechanisms to survive the attack from our agents, 
while laboratories developing new ones decrease. This has become a global health problem as 
mechanisms for resistance have been reported for all known antimicrobials currently available 
for clinical use in human and veterinary medicine [5].  
A bacterium’s susceptibility and resistance to antibiotics can be defined in two ways; from a 
clinical point of view and from a microbial point of view. In a clinical point of view a 
bacterium is defined as resistant if it is not killed or inhibited by the maximum dose of a given 
antimicrobial agent. It’s defined as susceptible if it responds to the therapy, and if the 
bacterium is not susceptible or resistant it’s defined as intermediate resistant. This means that 
it might be removed if the concentration of the antibiotic is increased. In a microbial point of 
view a resistant bacterium possess resistance mechanisms expressed phenotypically or 
genotypically, whereas a susceptible bacterium lacks these properties [7].  
 
Mechanisms of resistance 
The main biochemical resistances mechanisms in bacteria are divided into four groups; (i) 
decreased import and increased export of the drug (mutated porins, up-regulated efflux 




hyperexpression or overproduction of the drug target, (iv) production of drug modifying or 
degrading enzymes (β-lactamase) [7, 8].  
Resistance mechanisms in bacteria can either be an intrinsic property of the bacterium or 
acquired. Intrinsically resistant bacteria are naturally resistant where examples of properties 
are impermeability and lack of a susceptible target. This type of resistance has no additional 
genetic alterations and applies to the whole specie. Acquired resistance occurs by 
chromosomal mutations (deletions, point mutations, inversions, insertions etc.) or by 
acquisition of new DNA through horizontal gene transfer (HGT) [8]. 
Mutations 
Chromosomal mutations occur randomly during the DNA replication at a very low frequency 
in all bacterial cells. The results of these mutations can be altered antibiotic targets, drug-
inactivation, up- or down-regulation of efflux systems, and loss or inactivation of porins. 
Most of these mutations only affect one antimicrobial class but mutations in porins and efflux 
channels may contribute to resistance against several antibiotics [8, 9]. 
Acquisition of new DNA 
Initially susceptible bacteria can acquire antibiotic resistance from genes encoding resistance 
through mechanisms of HGT like conjugation, transformation and transduction. Transfer can 
occur between strains of the same species and between species or genera. Mobilizable 
elements carrying these genes are plasmids, transposons, bacteriophages or chromosomal 
DNA fragments called pathogenicity islands (PAIs) [10].   
Conjugation is the process when a donor bacteria transfer DNA, a self transmissible or 
mobilizable plasmid, to a recipient bacteria. This mechanism involves a separation of the 
mobile element into two strands where one of the strands move into the recipient, and both 
strands functions as templates replicating a complete double stranded molecule in each 
bacterium after the transfer. The recipient bacterium is called a transconjugant after it has 
received DNA from the donor. Other DNA in the cell can also be transferred along with the 
self-transmissible plasmid or DNA element. Gram-negative bacteria transfer plasmids through 
a pilus, an elongated proteinaceus structure, to adjacent bacteria. Gram-positive bacteria may 






Transformation involves the uptake of naked DNA, where DNA is released from the donor 
into the environment after cell lysis and taken up by a recipient cell, to become the 
transformant. If the new DNA is incorporated with its chromosomal DNA, a recombinant type 
of that bacterium will occur. Some bacteria are naturally transformable taking up 
environmental DNA by themselves while other bacteria need chemical or electrical treatment 
to become transformable. The uptake of DNA usually happens during a certain stage in the 
life cycle of bacteria that are naturally competent. 40 species are identified as naturally 
transformable today, including both Gram-negative (Haemophilus influenza, Helicobacter 
pylori) and Gram-positive bacteria (Bacillus subtilis, Streptococcus pneumonia). This 
mechanism is widely used in molecular genetics being the most convenient way to introduce 
new or altered DNA into a cell [6, 10, 12]. 
Transduction mechanism involves a bacteriophage transferring resistance genes from one 
bacterium to another. A transducing phage multiplies and accidently pack bacterial DNA into 
the phage head. Strains infected by the phage also receive the bacterial resistance genes. 
There are two types of transduction; generalised transduction transfers any region of DNA 
and specialised transduction transfers only DNA close to the attachment site of a lysogenic 
phage in the chromosome. This event rarely occurs because the incident of a phage packing 
host DNA by mistake is rare and transduced DNA must survive in the recipient cell to form a 
stable transductant [6, 10].  
 
Resistance elements 
Plasmids are extra-chromosomal genetic elements found in virtually all bacterial cells. They 
are self-replicating, transferable and mostly double-stranded covalently closed circular 
elements. Cells can contain several different plasmids, which can exist in multiple copies, 
differing in size, host range, transmission and their modes of replication. Even though 
plasmids are self-replicating they are dependent on both self-encoded and host-encoded 
factors in order to duplicate their genetic material. Plasmid copy number is defined by the 
number of copies of a certain plasmid in the cell directly after cell division. Some plasmids 




initiation of replication and partitioning is important so the plasmids are not lost or becomes a 
burden for the bacterial cell. Plasmids are classified into different incompatibility (Inc) groups 
according to their ability to coexist stably in the same cell. Those not able to coexist are the 
ones sharing common replication or partitioning systems, belonging to the same Inc-group. 
This results in an inability to control the copy number and plasmids may be cured from its 
host cell [13]. Plasmids are excellent cloning vectors as they are easy to purify, do not kill the 
host cell and can be made relatively small [10]. In a plasmid cloning vector, the inserted DNA 
will be replicated along with the vector, yielding many copies (clones) of the wanted DNA 
fragment [10, 13, 14]. 
Transposons are DNA elements able to move, transpose, from one place to another in the 
bacterial genome. Transposons exist in all organisms and the moving mechanism is called 
transposition. They have little or no target specificity facilitating insertion into any place in 
the genome. There are several different types of transposons, but generally they contain a 
transposase promoting transposition, inverted repeats in the ends, and short direct repeats of 
target DNA bracketing the transposons. Insertion sequence (IS) elements, composite 
transposons and non-composite transposons are all types of transposons able to carry around 
resistance genes from the chromosome to plasmids or the other way around. Conjugative 
transposons are another type containing genes for conjugative transfer from one bacterium to 
another. They are promiscuous transferring resistance genes between both Gram-negative and 
Gram-positive bacteria. Transposition is highly regulated and only occurs rarely [10, 15].  
Integrons are genetic elements integrated in transposons found on groups of plasmids and in 
the bacterial chromosome. These gene capturing systems are evolved from site-specific 
recombination mechanisms, and a general integron encode a DNA integrase gene (int) and an 
adjacent recombination site (att1) [16]. Structurally they comprise two terminal invariable 
regions, constant sequences (CS), and a variable central section. In the variable site there’s 
inserts of variable resistance genes integrated as gene cassettes. The gene cassettes are 
integrated in the attachment site (attI) of the integron which can contain many cassettes at 
once [14]. They can promote resistance to a wide variety of antibiotics (multiresistance). 
Integrons are unable to move by themselves, but their gene cassettes can be mobilized to other 
integrons or to secondary sites in the bacterial genome [16]. However integrons are often 




found in gram-negatives like Enterobacteriaceae and plays an important part in the spread of 
antibiotic resistance [17]. 
 
β-lactam antibiotics 
β-lactam antibiotics are one of the most important groups of antimicrobial agents 
administered worldwide, covering as much as 50% of all prescribed drugs. This is because 
they are highly effective and the side-effects are minimal. The β-lactams belongs to the group 
of antimicrobial agents inhibiting the cell wall synthesis. They have a bactericidal effect on 
the microorganisms and are classified into several groups; penicillins, cephalosporins, 
cephamycins, carbapenems, monobactams, and the β-lactamase inhibitors. The different 
groups consist of both natural and synthetic compounds varying in their chemical structure 
with the β-lactam ring as the common property. Each group have different ring structures and 
acyl side chains attached to the β-lactam ring [3, 7, 18].  
Mechanism of action 
Cell wall synthesis in bacteria is dependent on the penicillin-binding-protein (PBPs) enzymes 
transpeptidases, carboxypeptidases and transglycosylases. These enzymes complete the final 
stages of cross-linking the peptidoglycan polymers in the wall. β-lactams interfere during this 
stage directly inhibiting one or several of the enzymes. They act with the serine hydroxyl 
group of PBPs, replacing the D-ala-D-ala segment of the amino acid side chain of 
peptidoglycan, resulting in an irreversibly inhibition of the PBPs. Inhibition leads to 
bacteriolysis caused by autolysins activation of the cells autolytic system. This happens when 
precursors of the cell wall accumulate and the wall is unable to resist osmotic pressure.  
Mechanisms of resistance 
Β-lactams efficiency is dependent on the targets accessibility, the degree of resistance to 
enzymatic inactivation by β-lactamases, and the ability of β-lactam to inhibit the target PBPs. 
Combinations or alterations of these parameters may result in resistance. The clinical 
important mechanisms of resistance are; enzymatic inactivation, alteration of the target site 




Resistance by enzymatic inactivation 
Antibiotic-inactivation enzymes, like β-lactamses, are the most important single cause of 
resistance to β-lactams. Over 700 unique enzymes have been identified and they are either 
chromosomally or plasmid mediated. These enzymes make biologically inactive products of 
the antibiotic by efficient hydrolysis of the amide bond in the β-lactam ring [19, 20]. 
Resistance by alteration of the target site 
Resistance caused by alterations in PBPs can occur by acquisition of a resistant PBP, 
increased target PBP number and reduced affinity of the target PBP. PBPs with reduced 
affinity are an important mechanism of resistance to β-lactams when β-lactamases are absent 
[19, 20]. 
Resistance by alteration in access to the target site 
Β-lactams diffuse through porin channels in the outer membrane to get access to their target; 
the PBPs. Mutations in the porin genes of Gram-negative bacteria confer a decrease in 
permeability in the outer membrane. Synergistic effects can occur with the expression of β-
lactamases or an active efflux, making the bacteria even more resistant [19, 20].  
 
Cephalosporins 
Cephalosporin was first identified in 1948 by Giuseppe Brotzu [21] and isolated from a 
fungus called Cephalosporium. Newton and Abraham isolated and purified the substance at 
Oxford University in 1955, and named it cephalosporin C. Cephalosporin C was acting very 
stable against penicillin β-lactamase and its in vivo activity and lack of toxicity was 
demonstrated by Florey in 1955 [21]. Numerous of cephalosporins have been developed since 
this year, and all commercially available cephalosporins are semi-synthetic [21]. 
Cephalosporins have the same mechanism of action and similar resistance mechanisms as 
penicillins.  
A classification scheme divides the cephalosporins into generations according to their 




has significantly greater Gram-negative antimicrobial properties than the preceding 
generations:  
(i)       Moderate spectrum 1st generation (e.g. cefazolin, cephalexin and cephaloridine); 
are effective alternatives for treating staphylococcal and streptococcal infections.  
(ii)       Gram-negative spectrum 2nd generation (e.g. cefuroxime, cefcaclor and cefoxitin); 
have a greater Gram-negative spectrum of activity, useful for treating E. coli, 
Klebsiella and Proteus infections.  
(iii) Broad spectrum 3rd generation (e.g. cefpodoxime, cefotaxime, ceftazidime and 
ceftriaxone); are not as effective against Gram-positive microorganisms as the first 
generation, but active against most members of the Enterobacteriaceae.  
(iv)      Extended spectrum 4
th
 generation (e.g. cefepime, cefpirome and cefluprenam); 
display an increased stability against enzymatic degradation by β-lactamases 
(AmpC β-lactamases in particular), and an enhanced ability to penetrate the porins 
in the outer membrane of Gram-negative bacteria. They have the ability to cross 
the blood brain barrier and are thus also effective in meningitis.   
Adapted from Naseer 2008 [7]. 
 
Figure 1.1. Schematic presentation of β-lactam antibiotics; Penicillins, Cephems (Cephalosporins, 
Cephamycins), Carbapenems, Monobactams and β-lactamase inhibitors, and subsequent sub-classes. Printed 





The most important β-lactam resistance mechanism in Gram-negative bacteria is the 
production of β-lactamase enzymes. These enzymes are encoded on both chromosomes and 
plasmids, and possess different substrate profiles, inhibition profiles, molecular mass, 
isoelectric points, amino acid sequences and molecular structure [7]. β-lactamases that are 
chromosomally encoded can be expressed from a constitutive promoter giving high- or low 
level expression (e.g. ampC gene in E. coli), or they can be expressed from an inducible 
promoter (e.g. ampC gene in Enterobacter) [19, 22].  
The first β-lactam hydrolysing enzymes were discovered in the 1940s in microorganisms like 
E. coli, S. aureus and B. cereus. This happened before penicillins were taken into use clinically 
and the term selective pressure did not exist. Today penicillins, cephalosporins, 
monobactams and carbapenems can all be hydrolysed by multiple members of the β-
lactamase family [23]. During the last 40 years new β-lactams have been developed to fight 
resistance, but these have selected for more effective β-lactamases as extended-spectrum β-
lactamases (ESBLs), plasmid-mediated AmpC enzymes and carbapenems-hydrolysing β-
lactamases (carbapenemases) [23-25].  
Several classification schemes have been proposed for the classification of β-lactamases over 
the years. The two most frequently used are Amblers structural classes and Bush, Jacoby and 
Medeiros functional groups. Amblers classes A, B, C and D are based on the enzymes primary 
sequence similarity and catalytic mechanism. Class A, C and D share the same mechanism of 
action utilising an active-site serine, while class B require divalent metal cations (Zn++) to 
catalyse β-lactam hydrolysis. Bush, Jacoby and Medeiros divide the enzymes into four groups 
based on their substrate and inhibitor profiles. Group 1 are the cephalosporinases not 
inhibited by clavulanic acid or EDTA, group 2 are the penicillinases, cephalosporinases and 
broad-spectrum β-lactamases which to some extent are inhibited by β-lactamase inhibitors, 
group 3 are the metallo-β-lactamases, hydrolysing penicillins, cephalosporins and 
carbapenems, resistant to clavulanic acid, and group 4 are the penicillinases not inhibited by 





Table 1.2. Classification schemes for bacterial β-lactamases 
Ambler classification scheme 
Class A Serine Based Penicillinases 
Class B Zinc based metallo-β-lactamases 
Class C Serine Based Cephalosporinases 
Class D Serine based oxacillinases 
  Bush-Jacoby-Medeiros Scheme 
Group 1 Cephalosporinases resistant to clavulanic acid 
Group 2 Penicillinases, cephalosporinases, and broad-spectrum  
 
β-lactamases susceptible to clavulanic acid 
2a Penicillinases 
2b Borad-spectrum penicillinases 
2be ESBLs 
2br Inhibitor resistant 
2c Carbenicillin hydrolysing 
2d Oxacillin hydrolysing 
2e Cephalosporinases 
2f Carbapenemases 
Group 3 Metallo-β-lactamases resistant to clavulanic acid 
Group 4 Penicillinases resistant to clavulanic acid 
 
β-lactamases catalyse the irreversible hydrolysis of the amide (C-N) bond in β-lactams, with 
the use of a water molecule, leading to ineffective antimicrobials. Class A serine β-lactamase 
general mechanism of action involves activation of Lys73 or Glu66 followed by a nucleophilic 
attack by Ser70 on the carbonyl carbon of the β-lactam ring. Class C and D β-lactamases have 
more or less the same mechanism even though the activation of Ser70 is unknown. The 
mechanism behind hydrolysis remains unclear for the class B β-lactamases [7, 24]. 
Beta-lactamases are located in the periplasmic space between the outer and cytoplamsmic 
membranes of Gram-negative bacteria [19]. 
Chromosomal β-lactamases are encoded and found in all Enterobacteriaceae, except from 
Salmonella. E. coli, Klebsiella, Proteus and Shigella spp produce low basal levels of the 
intrinsic AmpC β-lactamase and are susceptible to ampicillin and other β-lactams. Examples 
of bacteria producing small amounts inducible AmpC β-lactamases are Enterobacter spp, 
Citrobacter freundii, Serratia, Morganella morganii, Providencia spp and Pseudomonas 




cephalosporins and are not inhibited by β-lactamase inhibitors, but only when the 
expression is high enough.  
Plasmid-mediated β-lactamases were identified in Gram-negative bacteria in the early 
1960s, and the TEM β-lactamases were the first ones[22]. During the 1970s plasmid encoded 
β-lactamases like TEM-1, TEM-2, SHV-1 (broad-spectrum) and OXA-1 (oxacillin-hydrolysing) 
had spread to Enterobacteriaceae, P. aeruginosa, Haemophilus influenza and Neisseria 
gonorrhoeae. It is believed that all plasmid-mediated β-lactamases has their origins from the 
chromosome. Chromosomal ampC genes of Enterobacter, C. freundii, Serratia and P. 
aeruginosa have moved onto plasmids which have been recovered from clinical isolates of E. 
coli and Klebsiella pneumonia. The source organisms are unknown for many types, and 
genes encoding these enzymes are often located on transposons [19, 22, 24]. SHV-2 was the 
first enzyme to hydrolyse newer β-lactams with an increased spectrum of activity (ESBL) and 
today numerous of TEM, SHV and OXA-derived ESBLs are identified. Resistance to β-
lactamase inhibitor/β-lactam drug combinations, penicillins, cephamycins, first, second, and 
third generations cephalosporins, and monobactams is seen in these strains. Susceptibility 
only to cefepime and imipenem is retained [19]. 
 
Class C β-lactamases – the AmpC cephalosporinases 
The first description of an AmpC β-lactamase came in 1940 and in 1965 scientists began to 
study the genetics behind these enzymes and their resistance [27]. This enzyme was 
identified in an E. coli isolate and had the ability to hydrolyse penicillin. In 1981 the whole 
sequence of the ampC gene in E. coli was obtained, which differed from the penicillinases 
sequence, but still with a serine at its active site [27]. Since the first AmpC enzyme was 
discovered, numerous of new variants have been identified [27]. Producers of the 
chromosomal AmpC β-lactamases are Gram-negative bacteria, where the majority is found 
in the Enterobacteriaceae family, including Citrobacter, Salmonella, Serratia, Enterobacter 
and Shigella. But these enzymes are also observed in strains like Pseudomonas, Aeromonas 




The AmpC cephalosporinases are classified into Amblers structural class C β-lactamases and 
into Bush, Jacoby and Medeiros functional group 1 [26]. 
Physically the AmpC enzymes location is in the periplasmic space of the bacteria. AmpC 
enzymes have a molecular mass between 34 and 40 kDa and isoelectric points usually above 
8 [27]. 
The enzymatic properties of the AmpC β-lactamases confer resistance to a variety of β-
lactams. These enzymes have the ability to hydrolyse penicillins, cephalosporins, 
cephamycins (cefoxitin, cefotetan), oxyiminocephalosporins (ceftazidime, cefotaxime, 
ceftriaxone) and monobactams (aztreonam) to a little extent. They are not inhibited by 
commercially available β-lactamase inhibitors. They are usually susceptible to carbapenems 
and fourth-generation cephalosporins (cefepime, cefpirome). Bacterial clinical isolates with 
mutated AmpC enzymes mediating reduced susceptibility to cefepime have been reported. 
Carbapenem resistance in an AmpC producing strain can be achieved by porin mutations or 
the loss of porins in the outer membrane. Inhibitors like clavulanic acid, sulbactam and 
tazobactam have little effect towards these enzymes (some are inhibited by tazobactam and 
sulbactam). They are poorly inhibited by p-chloromercuribenzoate and not at all by EDTA. 
Good inhibitors are substances like cloxacillin, oxacillin and aztreonam, and boronic acid 
reversibly inhibiting AmpC [20, 24, 27, 28].  
The expression of AmpC β-lactamase is usually low but can be inducible by a complex 
mechanism linked to the ampR gene. Overexpression is linked to mutations in AmpD and 
AmpR leading to hyperinducibility or constitutive hyperproduction of the enzyme. Mutations 
in AmpG can lead to constitutive low-level expression. Additional features to AmpC 
regulation is found in different bacteria. Examples are E. coli and Shigella both lacking AmpR 
which confer noninducible AmpC production regulated by promoter and attenuator 
mechanisms instead. The amount of AmpC enzymes are important to the resistance, as well 






Porin channels and efflux pumps plays an important role for the resistance spectrum. The 
concentration of a β-lactam in the periplasmic space is dependent on the outer membranes 
permeability. A decrease in porin channels or an increase of efflux pumps will lower the 
amount of β-lactams in the periplasmic space leading to higher enzyme efficiency. Molecules 
with both positive and negative charges (cefepime and cefpirome) penetrate the outer 
bacterial membrane faster than molecules with a net positive charge (cefotaxime, 
ceftriaxone) [27, 29]. 
Plasmid-mediated AmpC β-lactamases have been found in isolates worldwide, and are 
capable to compromise the use of β-lactams. CMY-1 was the first enzyme discovered in a K. 
pneumoniae isolate in South Korea 1989[30]. Plasmid encoded AmpC enzymes are divided 
into families according to differences in their amino acid sequences. There are 43 variants of 
CMY, 7 variants of FOX, 4 variants of ACC, LAT and MIR, 3 variants of ACT and MOX, and 2 
variants of DHA [27]. Plasmid determined enzymes can be very closely related to certain 
chromosomal AmpC β-lactamases, and amino acid sequence similarity can be 100% for some 
groups. They confer resistance to penicillins, oxyimino-β-cephalosporins, cephamycins, and 
variably to aztreonam. They are susceptible to cefepime, cefpirome, and carbapenems, and 
inhibited by aztreonam, cloxacillin and boronic acid. Their molecular size range from 38 to 42 
kDa, and the size of their plasmids vary between 7 to 180 kb. Bacteria carrying plasmid-
mediated AmpC enzymes are often multiresistant encoding resistance against antibiotics like 
aminoglycosides, chloramphenicol, sulfonamide and tetracycline. Plasmid-borne ampC 
genes are usually not inducible because of the absence of ampR regulatory gene. Genetic 
elements involved in the mobilization of the ampC genes onto plasmids are transposable 
elements (transposons) and integron like elements. The IS-element ISEcp1 is involved in the 
transposition and mobilization of chromosomal bla genes onto plasmids (CMY family), and 
insertion sequence common region (ISCR1) is associated with gene mobilization into 
complex class 1 integrons. Plasmid-borne ampC genes are not associated with characteristic 






Extended-spectrum cephalosporinases with enhanced hydrolysis activity against oxyimino-
β-lactam substrates are described for both chromosomal and plasmid-mediated AmpC 
enzymes. Alterations in the amino acid sequence like insertions, deletions and substitutions 
occur in the Ω-loop or near the R2 loop. Ω-loop mutations make the enzyme more accessible 
for substrates with bulky R1 side chains. An R2 loop mutation makes this binding site wider. 
The opposite effect can occur on both mutation sites. Structural gene mutations are often 
followed by promoter mutations increasing the level of expression of the mutant gene [27, 
32].  
Clinical relevance 
Gram-negative bacteria that are able to develop hyperexpression of AmpC β-lactamases are 
clinically important. Several studies have confirmed that patients treated with broad-
spectrum cephalosporins developed bacterial strains showing a decrease in their 
susceptibility. This development of resistance upon therapy is a great concern [27].  
 
Escherichia 
The genus Escherichia is a small group of Gram-negative rods classified under the family of 
Enterobacteriaceae. Escherichia comprise a total number of six species including Escherichia 
albertii, E. blattae, E. fergusonii, E. hermannii, E. vulneris and E. coli. They are widely 
distributed in the intestines of humans and animals. Escherichia are facultative anaerobic, 
non-sporulating, motile with peritrichous flagella or non-motile. They ferment D-glucose and 
other sugars, catalase positive, oxidase negative, reduce nitrate to nitrite, and have a GC 
content between 39 and 59% in their DNA [33]. 
 
Escherichia coli 
E. coli is the one most often isolated from human specimens of all the six species. It is almost 
a permanent constituent of the bowel flora of healthy individuals, and may also colonize the 




an opportunistic pathogen for both humans and animals. E. coli is capable to cause 
extraintestinal and intestinal infections in both healthy and immunocompromised 
individuals. Pathogenic clones of E. coli can cause urinary tract infections (UTI), diarrheal 
diseases, neonatal meningitis and septicaemia, and is one of the most versatile of all 
bacterial pathogens. The main route for transmission is contact and ingestion (faecal-oral), 
and presence of E. coli in water or food implies faecal contamination. Contamination is 
usually associated with pathogenic strains. The bacterium possesses O (somatic), H 
(flagellar), K (capsular) and F (fimbrial) antigens which can be used to characterise 
pathogenic strains by serotyping [3, 33]. 
 
Clinical significance 
E. coli is one of the most common causes of hospital acquired infections, and accounts for 
more infections than any other single species overall. One million deaths per year are caused 












Aims of study 
1. Characterise Norwegian clinical E. coli isolates for genetic alterations in the 
chromosomal ampC gene that can lead to increased resistance to cephalosporins by an 
increase of the mRNA level. 
a. Mutations in the ampC gene control region 
b. Mutations in the ampC gene coding region 
2. Characterise the functional properties of mutations in the ampC gene coding regions 
that can change the catalytic efficacy of the AmpC enzymes against extended 




















A total of 55 clinical E. coli isolates with a chromosomal AmpC phenotype where chosen for 
this study. All strains where collected from 12 diagnostic Norwegian clinical microbiology 
laboratories over a time period from 2003 through 2007. Prior to this study each laboratory 
performed antimicrobial susceptibility testing in agreement with the Norwegian Working 
Group on Antibiotics (NWGA) guidelines and the recommendations of the European 
Committee for Antimicrobial Susceptibility Testing (EUCAST). The Norwegian Reference 
Centre for Detection of Antimicrobial Resistance (K-res) received and tested the strains 
further to establish a final resistant profile with a panel of β-lactam Etests. AmpC multiplex 
PCR was carried out to exclude presence of plasmids and acquired ampC genes.  
 In this study the main group of isolates that was characterised had an AmpC phenotype with 
reduced susceptibility to third generation cephalosporins, without clavulanic acid synergy. 
Three of the chosen isolates for this study did not fulfil the AmpC phenotype selection 
criteria, expressing intermediary susceptibility to fourth generation cephalosporins, with 
clavulanic acid synergy. Etest selection criteria for the chosen AmpC phenotype isolates 
where cefotaxim and ceftazidim (3
rd
 generation) MIC values >4. The Etest selection criteria 
for the three isolate not expressing the AmpC phenotype where cefepime (4
th
 generation) MIC 
values ≥1. The information on clinical isolates is given in Table 2.1 and for the complete Etest 









Table 2.1. Data from clinical and sensitive isolates and control strains             
    
  MIC Etest (mg/L)     
  





K2-68 Ullevål 2003 Nasal secretion 4 16 64 96 <0.25 Pos Neg 
K4-30 Ahus 2003 Urine 6 16 256 256 0.5 Pos Neg 
K4-37 Ullevål 2003 Blood 4 12 96 64 0.38 Pos Neg 
K8-02 Vestfold 2003 Pus 16 12 >256 256 0.25 Pos Neg 
K9-38 UNN 2004 Operationwound 6 8 64 64 <0.25 Pos Neg 
K9-66 Stavanger 2004 Urine 6 16 256 192 <0.25 Pos Neg 
K14-27 Vestfold 2004 Urine 6 24 256 128 0.38 Pos Neg 
K14-35 Vestfold 2004 Matter 32 64 >256 >256 1.5 Pos Neg 
K15-08 Molde 2004 Blood 3 16 128 64 0.38 Pos Neg 
K22-31 Telelab 2005 Urine 4 24 192 128 <0.25 Pos Neg 
K25-19 Vestfold 2005 Urine 6 16 256 >254 <0.25 Pos Neg 
K25-65 Haukeland 2005 Blood 12 12 128 >256 3 Pos Neg 
K29-48 Haukeland 2005 Urine 4 6 128 48 <0.25/0.094 Pos Neg 
K29-77 Haukeland 2006 Bloodculture 4 6 256 96 <0.25/0.125 Pos Neg 
K29-80 Haukeland 2006 Urine 4 8 256 64 <0.25/0.094 Pos Neg 
K30-01 Haukeland 2006 Urine 4 48 128 256 <0.25/0.19 Pos Neg 
K30-18 Vestfold 2006 Urine 4 12 64 128 <0.25/0.064 Pos Neg 
K30-39 Telelab 2006 Urine 8 24 > 256 256 0.25/0.19 Pos Neg 
K30-44 Haukeland 2006 Urine 3 6 192 48 3/4 Pos Neg 
K30-45 Østfold 2006 Bloodculture 4 8 192 64 <0.25/0.125 Pos Neg 
K33-01 Østfold 2006 Urine 4 12 128 64 <0.25/0.125 Pos Neg 
K33-03 Haukeland 2006 Urine >256 24 32 > 256 >16/<0.064 Pos Neg 
K33-24 Østfold 2006 Urine 3 2 256 8 1.5/0.38 Pos Neg 
K33-54 Østfold 2006 Urine 4 12 256 128 0.25/0.094 Pos Neg 
K34-08 Haukeland 2006 Urine 4 4 192 64 <0.25/0.094 Pos Neg 
K34-10 Vestfold 2006 Pus 4 8 128 64 <0.25/0.125 Pos Neg 
K34-32 Østfold 2006 Urine 4 8 > 256 96 <0.25/0.094 Pos Neg 
K34-43 UNN 2006 Urine 8 24 256 128 0.38/0.38 Pos Neg 
K34-61 Telelab 2006 Unknown 6 32 256 96 <0.25/0.125 Pos Neg 
K34-69 Vestfold 2006 Abscess 4 6 96 64 <0.25/0.094 Pos Neg 
K34-76 UNN 2006 Urine 6 8 64 64 0.75/0.5 Pos Neg 
K36-13 Ullevål 2006 BAL 6 >32 192 256 0.38/0.125 Pos Neg 
K36-22 Sørlandet 2006 Urine 4 6 128 64 <0.25/0.094 Pos Neg 
K36-30 Sørlandet 2006 Urine 4 8 32 64 <0.25/0.094 Pos Neg 
K36-50 Østfold 2007 Urine 4 16 48 96 <0.25/0.094 Pos Neg 
K41-19 UNN 2007 Urine 4 16 64 64 <0.25/0.19 Pos Neg 
K41-22 Haukeland 2007 Blood 6 16 96 96 <0.25/0.125 Pos Neg 
K41-34 Haukeland 2007 Blood 4 6 192 64 <0.25/0.125 Pos Neg 
K41-39 Haukeland 2007 Urine 4 6 256 64 <0.25/0.125 Pos Neg 
K41-52 Haukeland 2007 Urine 4 8 96 64 <0.25/0.125 Pos Neg 
K41-53 Ålesund 2007 Blood 4 16 256 96 0.25/0.125 Pos Neg 
K41-64 Vestfold 2007 Abscess 48 128 96 > 256 0.5/0.38 Pos Neg 
K41-71 Sørlandet 2007 Urine 4 4 > 256 48 0.38/0.19 Pos Neg 
K44-58 UNN 2007 Urine 4 6 192 64 <0.25/<0.064 Pos Neg 
K44-60 Haukeland 2007 Urine 2 3 96 6 1/0.19 Pos Neg 
K44-77 Haukeland 2007 Urine 4 16 96 128 <0.25/<0.064 Pos Neg 
K45-79 Vestfold 2007 Urine 4 8 128 64 <0.25/<0.064 Pos Neg 
K46-03 Sørlandet 2007 Urine 4 16 96 64 <0.25/0.094 Pos Neg 
K46-23 Ullevål 2007 Urine 32 48 96 > 256 0.38/0.25 Pos Neg 
K46-34 Haugesund 2007 Urine 6 12 64 96 <0.25/0.125 Pos Neg 
K46-40 UNN 2007 Urine 8 8 > 256 256 <0.25/<0.064 Pos Neg 
K46-46 Levanger 2007 Blood 24 128 > 256 > 256 0.38/0.38 Pos Neg 
K46-48 Haukeland 2007 Operationwound 4 8 128 48 <0.25/<0.094 Pos Neg 
K46-52 UNN 2007 Blood 4 12 64 96 <0.25/0.125 Pos Neg 
K46-73 UNN 2007 Urine 8 48 > 256 256 <0.25/0.094 Pos Neg 
ATCC 
25922 Control Unknown Unknown <1 <1 <4 <0,25 ND ND ND 
*test results withot clavulanate acid were tested by diskdiffusion 






Table 2.2. Bacterial growth media used in this study 
Medium Content 
Brain Heart Infusion Broth (BHI) Oxoid Brain Heart Infusion, dH₂O 
Mueller Hinton agar Difco Mueller Hinton medium, dH₂O 
Green agar with 100 µg/L 
Ampicillin 
 Green agar 
 
  Deep freeze culture broth Oxoid Brain Heart Infusion, glycerol (Merck), dH₂O 
LB broth 
 LB agar 
 LB agar with 50 µg/L Kanamycin 
 LB agar with 100 µg/L Ampicillin 





















Table 2.3. Chemicals and reagents used in this 
study   
Method Chemicals Contents 
Electrophoresis 
of DNA SeaKem® LE Agarose LONZA 
 
Gel loading buffer 6x Promega 
 
Ethidium Bromide  Sigma, Germany 
 
1 Kb plus DNA ladder New England Biolabs, Beverly, USA 
 
0.5 x TBE buffer with pH 8.0 Tris-Base, borate, EDTA 











Piperacillin, Etest strips with 
















Cefuroxime, Etest strips with 





Cefpodoxime, Etest strips with 





Cefotaxime, Etest strips with 





Cefotaxime/clavulanic acid, Etest 





Ceftazidime/clavulanic acid, Etest 





Cefepime/clavulanic acid, Etest 










Meropenem, Etest strips with 





Ceftazidime , Etest strips with 
range AB Biodisk, Solna, Sweden 
 
0.016-256 µg/ml 
 PFGE Low range PFGE Marker New England Biolabs, Beverly, USA 
 
PIV-buffer 10 mM Tris-HCl pH 7.6, 1 M NaCl 
 
Basis-buffer 
100 mM EDTA, 6 mM Tris-HCl pH 7.6, 1 M NaCl, 0.5% 
Brij 58 
 
TE-buffer 10 mM Tris-HCl pH 8.0, 0.1 mM EDTA 
 
10 x TBE buffer, pH 8.0 108 g Tris-base, 55 g boric acid, 9.3 g EDTA, 
  
dissolve in ddH₂O to 1000 ml 
 
Lysis-buffer (for 5 plugs) 10 ml basic buffer, 0.02 g deoxycholate, 
  
 0.05 g N-laurosylsarcosine, 0.01 g lysozyme (1 mg/ml),  
  





Proteinase K Stock Solution 
100 mg Proteinase K, 10 ml 50 mM Tris-Cl pH 8.0, 10 
mM CaCl₂  
 
ESP-buffer 0.5 M EDTA pH 9-9.5, 1% Na-laurylsarcosine 
 
2% LMP agarose 10 ml PIV buffer, 0.2 g LMP agarose 




polyacrylamide gel, pH 3.5-9.5 GE Healthcare, Oslo, Norway 
 





Cathode solutions 1 M NaOH 
 
Anode solutions 1 M H₃PO₄  
 










30 mM KAc, 100 mM RbCl, 10 mM CaCl₂x2H₂O, 50 
mM MnCl₂x4H₂O, 15% Glycerol   
  TFB2 
10 mM MOPS, 75 mM CaCl₂xH₂O, 10 mM RbCl, 15% 
Glycerol      
 
Table 2.4. Kits and enzymes used in this study   
Method Reagents, kits and enzymes Producer 
Isolation of DNA MagAttract DNA Mini M48 kit (192) 






JumpStart RED Taq 
 Purification of PCR 
products E.Z.N.A Cycle Pure Kit 
 
 





 DNA sequencing BigDye®Terminator v3.1 Cycle Sequencing Kit Applied Biosystems 
Isolation of RNA RNAprotect® Bacteria Reagent Qiagen 
 
RNeasy® Mini Kit Qiagen 
cDNA synthesis High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 









 Isolation of plasmid E.Z.N.A Plasmid Midiprep Kit 
 
 
E.Z.N.A Plasmid Miniprep Kit 
 Cloning pGEM®-T Easy Vector Systems 
 
 
pBK-CMV Phagemid Vector Cloning Kit 
 
 
2 x Rapid Ligation Buffer, T4 DNA Ligase 
 
 
T4 DNA Ligase (3 Weiss units/µl) 
 
 









100 x BSA Buffer 
 
 
10 x T4 Ligase Buffer 





Table 2.5. Oligonucleotide primers used for PCR and direct sequencing   
PCR Primer Sequence 5'-3' References 
AmpC whole region ampC F TTCCTGATGATCGTTCTGCC Mammeri et al., 2008 
 
ampC R AAAAGCGGAGAAAAGGTCCG Mammeri et al., 2008 
AmpC whole region 
ampC 
intF GGTTCGGTCAGCAAAACATT This study 
 
ampC 
intR GCAAGTCGCTTGAGGATTTC This study 
16S rDNA 16S F AGAGTTTGATCMTGGCTCAG Weisburg et al., 1991 
 
16S R ACGGHTACCTTGTTACGACTT Weisburg et al., 1991 
MLST adk F ATTCTGCTTGGCGCTCCGGG Achtman et al., 2006 
 
adk R CCGTCAACTTTCGCGTATTT Achtman et al., 2006 
 
fumC F TCACAGGTCGCCAGCGCTTC Achtman et al., 2006 
 
fumC R GTACGCAGCGAAAAAGATTC Achtman et al., 2006 
 
gyrB F TCGGCGACACGGATGACGGC Achtman et al., 2006 
 
gyrB R ATCAGGCCTTCACGCGCATC Achtman et al., 2006 
 
icd F ATGGAAAGTAAAGTAGTTGTTCCGGCACA Achtman et al., 2006 
 
icd R GGACGCAGCAGGATCTGTT Achtman et al., 2006 
 
mdh F ATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGG Achtman et al., 2006 
 
mdh R TTAACGAACTCCTGCCCCAGAGCGATATCTTTCTT Achtman et al., 2006 
 
purA F CGCGCTGATGAAAGAGATGA Achtman et al., 2006 
 
purA R CATACGGTAAGCCACGCAGA Achtman et al., 2006 
 
recA F CGCATTCGCTTTACCCTGACC Achtman et al., 2006 
 
recAR TGTTCGAAATCTACGGACCGGA Achtman et al., 2006 
Cloning ampC gene EcoRI F ATATGAATTCTTTTGTATGGAAACCAGACC Mammeri et al., 2008 
 
NotI R ATATGCGGCCGCAAAAGCGGAGAAAAGGTCCG Mammeri et al., 2008 
pGEM-T easy vector pGEM F CAGGGTTTTCCCAGTCAC Promega 
 
pGEM R GCGGATAACAATTTCACAC Promega 
pBK-CMV phagemid 
vector T3 F AATTAACCCTCACTAAAGGG Stratagene 











Preparation of stock cultures (B-culture) 
A stock culture of bacteria is stored in -70°C (deep freeze storage) and prepared from a freeze 
broth containing an osmotic protector such as glycerol or DMSO. 
Procedure: 
1. 8-10 overnight colonies was taken from an overnight incubated plate and 
inoculated in 1 ml freeze broth. 
2. The broth was homogenized on a vortex mixer and stored at -70°C. 
3. Control plates were inoculated and incubated at 37°C overnight to check for 
contamination. 
4. If the control plate was contaminated the strain was purified by re-incubating it on 
a new plate before storage. 
 
(Freezing of bacterial strains, version 1.4? Methodology, General Bacteriology section, 
Department of Microbiology, University Hospital of Northern Norway)  
 
Rubidiumchloride (RbCl) Competent cells 
In this method the cell walls of the bacteria were treated with rubidium chloride to make them 
competent.  
Procedure: 
1. 1% of an overnight LB broth culture was inoculated in 100 ml Psi-broth, and 
incubated at 37°C until OD600 showed 0.4, approximately two hours after 
incubation. 
2. The suspension was incubated on ice for 15 minutes and then centrifuged for five 




3.  The supernatant was discarded and the pellet resuspended in 40 ml cold TFB1, 
and incubated on ice for five minutes. 
4. A new round of centrifugation was performed at 4500 rpm for five new minutes. 
5. The supernatant was discarded and the pellet resuspended in 3 ml cold TFB2. 
6. The suspension was then dispersed 100 µl in 30 Eppendorftubes and immediately 
frozen on dry ice. 




Isolation of DNA from bacterial cells 
Two different methods were performed isolating DNA from the bacterial strains; rapid 




Rapid template isolation of DNA for PCR 
Rapid template isolation allows fast and easy preparation of PCR-amplifiable DNA. A simple 
boiling step makes the bacterial cell lysate, and DNA becomes available for the PCR 
amplification process.  
Procedure: 
1. 8-10 bacterial colonies were collected and dissolved in 1 ml TE-buffer in an 
Eppendorftube. 
2. After centrifugation for 5 minutes at 5000 rpm, the supernatant was discarded. 
3. The pellet was resuspended in 100µl TE-buffer. 
4. The sample was boiled for 10 minutes at 100°C, and spun for 5 minutes at 5000 
rpm. 
5. The Eppendorftube was placed on ice, and supernatant was transferred to a new 





(Extraction of DNA from bacteria, version 1.0, Methods for DNA work, Department of 
Medical Microbiology, University of Tromsø) 
 
Isolation of DNA using the robot GenoM
TM




-48 robot uses the technology of GenoPrep
TM
 products and performs all steps 
of the DNA isolation procedure, including lysis, washing steps and elution. This isolation of 
DNA relies upon the binding of DNA to the GenoPrep
TM
 Beads. These are magnetic and 
DNA has a tendency to bind to the silica (glass) surface of the magnetic beads in the presence 
of a chaotropic salt solution (sodium iodide, guanidinium thiocyanate or guanidinium 
hydrochloride).    
Procedure: 
1. An inoculum of 0.5 McFarland was prepared in 0.9% NaCl. 
2. The sample tubes were placed on the robot. 
3. The robot performed all steps of isolation, including sample lysis, binding to the 
GenoPrep
TM
 beads, washing steps and the elution. 
4. When finished the screw caps were replaced and samples were stored at 2 to 8°C. 
 









Amplification of DNA 
Polymerase Chain Reaction (PCR) 
The PCR is used for enzymatic amplification of a specific or defined DNA fragment in vitro. 
The reaction requires a DNA template, complementary oligonucleotide primers, dNTPs and 
heatstable DNA polymerase. The PCR thermocycler is a heating block that rapidly change 
between temperatures and can be programmed to do this in different cycles. PCR 
amplification of DNA involves three stages with alternating temperatures. In the first stage, at 
94°C, DNA is completely denatured to single-stranded DNA. The second stage, at 40-60°C, 
involves annealing to the target DNA by primers complementary to the 3’ ends of opposite 
strands of the DNA. In the third stage, at 72°C, DNA polymerase extends each primer, 
duplicating the target sequence. These three stages are repeated 30 to 40 times yielding new 
duplicates every cycle, resulting in many copies of the wanted DNA fragment, the PCR 
product. 
Procedure: 
1. The mastermix contents were thawed on ice before use, and the PCR mastermix 
was made on a separate bench to avoid contamination. See table 3.1 for a general 
PCR reaction recipe. 
2. The PCR mastermix and template were transferred to special PCR tubes and spun 
down with a mini centrifuge. 
3. The tubes were placed on the PCR machine and the PCR program, with the right 
cycling conditions pre-installed, was started. See table 3.2 for a general PCR 
cycling program. 
Table 3.1. Mastermix contents for a general 
PCR 
Mastermix contents Quantity 
Reddy Mix x2 25 µl 
ddH2O 19 µl 
Primer Forward (50 pmol/µl) 1 µl 
Primer Reverse (50 pmol/µl) 1 µl 
Template 4 µl 





Table 3.2. General PCR cycling program   
Step Temperature Time Cycles 
Initial denaturation 94/95°C 2-5 min 
 Denaturation 94/95°C 30-60 sec  x 30 
Annealing *) 30-90 sec  x 30 
Elongation 72°C 90-120 sec  x 30 
Terminal elongation 72°C 5 min 
 Hold 4°C ∞  
      *) Primer melting temperature 
 
(Principle for PCR version 2.0, Department of microbiology and virology, IMB, University of 
Tromsø.) 
PCR-based detection of ampC β-lactamase gene control and gene coding regions 
For specific mastermix contents and PCR cycling program parameters used in this PCR-
reaction see Table 3.3 and Table 3.4. 
Table 3.3. Mastermix contents for ampC whole region 
PCR 
Mastermix contents Quantity 
Reddy Mix x 2 25 µl 
ddH₂O 19 µl 
Primer Forward (50 pmol/µl) *) 1 µl 
Primer Reverse (50 pmol/µl) *) 1 µl 
Template 4 µl 
Total volume 50 µl 
       *) See Table 2.5. 
 
 
Table 3.4. ampC gene control and coding region PCR cycling 
program 
Step Temperature Time Cycles 
Initial denaturation 94°C 3 min   
Denaturation 94°C 30 sec  x 30 
Annealing 55°C 30 sec  x 30 
Elongation 72°C 90 sec  x 30 
Terminal elongation 72°C 5 min 





PCR-based detection of ampC β-lactamase gene coding region 
For specific mastermix contents and PCR cycling program parameters used in this PCR-
reaction see Table 3.5 and Table 3.6. 
Table 3.5. Mastermix contents for AmpC Cloning PCR 
Mastermix contents Quantity 
Reddymix x 2 25 µl 
ddH₂O 19 µl 
Primer forward (50 pmol/µl) *) 1 µl 
Primer reverse (50 pmol/µl) *) 1 µl 
Template 4 µl 
Total volume 50 µl 






Table 3.6. blaampC gene coding region PCR cycling program 
Step Temperature Time Cycles 
Initial denaturation 94°C 3 min   
Denaturation 94°C 30 sec  x 30 
Annealing 56°C 30 sec  x 30 
Elongation 72°C 90 sec  x 30 
Terminal elongation 72°C 5 min 




16S rDNA PCR 
The identification of different species in bacteria can be established with both phenotypic and 
genotypic methods. Phenotypic methods are often not completely reliable because all strains 
within a given specie not necessarily are positive for a common property. And it’s proven that 
the same strain can possess biochemical variability. Genotypic methods are therefore 
developed based on analysis of PCR products derived from selected target DNA sequences 




often used as an alternative or supplement to traditional identification techniques. The rRNA 
genes are highly conserved and present in all bacteria containing some sequence areas with 
sequence specific variations that can be used in taxonomic characterisation. Universal primers 
recognising 16S rDNA from most bacteria are used for amplification and sequencing. 
For specific mastermix contents and PCR cycling program parameters used in this PCR-
reaction see Table 3.7 and Table 3.8. 
Table 3.7. Mastermix contents for 16S rDNA 
PCR 
Mastermix contents Quantity 
JumpStart RED Taq 12.5 µl 
ddH₂O 9.6 µl 
16S rDNA F (50 pmol/µl) *) 1 µl 
16S rDNA R (50 pmol/µl) *) 1 µl 
Template 2.5 µl 
Total volume 25 µl 
     *) See Table 3.5. 
 
Table 3.8. 16S rDNA PCR cycling program 
  
Step Temperature Time Cycles 
Initial denaturation 95°C 1 min   
Denaturation 95°C 30 sec  x 30 
Annealing 55°C 30 sec  x 30 
Elongation 72°C 60 sec  x 30 
Terminal elongation 72°C 7 min 
 Hold 4°C ∞   
 
The PCR products were pre-sequenced, sequenced and detected automatic with ABI 
PRISM
TM
 3100 Genetic Analyser (PE Biosystems) (see below). The obtained sequences were 
compared to 16S rDNA sequences available in GenBank-, EMBL- and DJB-databases by the 
BLASTN program on NCBIs homepage: http://www.ncbi.nlm.nih.gov/BLAST/.  
(Identifying genotype, version 1.1 Methodology, General Bacteriology section, Department of 








Multi locus sequence typing (MLST) PCR 
Multi-locus sequence typing (MLST) is a typing technique utilising multiple housekeeping 
genes loci in characterisation of isolates from particular bacterial species. This method takes 
advantage of the variation present in the nucleotide sequences of these gene fragments. All the 
unique sequences for a given locus are assigned a novel allelic number. The combination of 
the multiple loci numbers defines a particular strains sequence type (ST). Relationships 
among the isolates are identified by comparing their allelic profiles. Isolates closely related 
have identical STs, or STs that differ at a few loci, while unrelated isolates have unrelated 
STs. Materials required for the ST determination are available in laboratories all over the 
world and the MLST data are easily exchanged. This technique can be highly automated and 
can be able to screen hundreds and thousands of samples in a short matter of time. MLST 
schemes are available for several prokaryotic and eukaryotic pathogens [35, 36].  
Procedure: 
1. The E. coli MLST uses internal fragments of the following seven housekeeping 
genes: 
 adk (adenylate kinase) 
 fumC (fumarate hydratase) 
 gyrB (DNA gyrase) 
 icd (isocitrate/isopropylmalate dehydrogenase) 
 mdh (malate dehydrogenase) 
 purA (adenylosuccinat dehydrogenase) 












2. The PCR amplification properties and the product length of the different genes: 
Gene  Product length Annealing temperature  
adk  583 bp   54°C 
fumC  806 bp   54°C 
gyrB  911 bp   60°C 
icd  878 bp   54°C 
mdh  932 bp   60°C 
purA  816 bp   54°C 
recA  780 bp   58°C  
3. All gene fragments with the same annealing temperature were run in the same PCR 
cycle reaction. For mastermix contents and PCR cycling program parameters see 
table 3.9 and table 3.10, respectively. 
4. The PCR products were pre-sequenced, sequenced and detected automatic with 
ABI PRISM
TM
 3100 Genetic Analyser (PE Biosystems) (see below). The 
sequences were blasted on MLSTs homepage 




Table 3.9. Mastermix contents for MLST 
PCR 
Mastermix contents Quantity 
RedTaq 12.5 µl 
ddH₂O 9.6 µl 
Primer Forward (50 pmol/µl) *) 0.2 µl 
Primer Reverse (50 pmol/µl) *) 0.2 µl 
Template 2.5 µl 
Total volume 25 µl 







Table 3.10. MLST PCR cycling program 
  
Step Temperature Time Cycles 
Initial denaturation 95°C 2 min   
Denaturation 95°C 60 sec  x 30 
Annealing 54-60°C*) 60 sec  x 30 
Elongation 72°C 120 sec  x 30 
Terminal elongation 72°C 5 min 
 Hold 4°C ∞   
       *) Primer melting temperature 
 
MLST was performed according to the scheme developed by Achtman et al [34] 
(http://web.mpiib-berlin.mpg.de). Sequence alignments were performed using BioEdit 
sequence Alignment Editor.  
 
BURST algorithm analysis (eBURST) 
The BURST algorithm is a simplified model for bacterial evolution trying to identify groups 
of related genotypes that are mutually exclusive based on MLST data. First the algorithm 
attempts to identify the founding (ancestral) genotype for each group, designated sequence 
type (ST). The founder is the ST with the greatest number of single locus variants (SLVs). In 
the next step genotype variants are predicted based on the way the clones have emerged and 
diversified from the founding genotype. Related genotypes are then clustered, centred on the 
predicted founder, and this cluster is referred to as a clonal complex (STC).   
 
The allelic profiles were obtained by BURST (Based Upon Related Sequence Types) analysis 






Agarose gel electrophoresis of DNA 
The most common way to separate DNA molecules according to size is electrophoresis in 
agarose or polyacrylamide gels. Electrophoresis in horizontal agarose gels stained with 
ethidium bromide (EtBr) is the most widely used method. EtBr binds to the DNA between the 
stacked base-pairs (bp) and is exhibiting a strong orange-red fluorescence when illuminated 
with ultraviolet light. Molecules larger than 200 bp are separated by agarose gels, and 
molecules smaller than this should be separated by polyacrylamide gels. Agarose is a linear 
polymer extracted from seaweed, with a basic structure consisting of D-galactose and 3,6-
anhydro-L-galactosidase. Agarose melts at 100°C and becomes solid again when the 
temperature decrease to under 50°C. The gel matrix solidified density is determined by the 
concentration of the agarose. DNA is negatively charged at a neutral pH value and will 
migrate toward the anode when an electric field is applied across the gel. Several parameters 
determine the migration rate; DNA molecular size, agarose concentration, composition of the 
electrophoresis buffer, DNA conformation, direction of the electrical field, and the presence 
of intercalating dyes. 
Procedure: 
1. A  1% agarose gel was made by adding agarose to 0.5 x TBE buffer. 
2. The agarose solution was boiled until all the agarose was dissolved in a microwave 
oven. 
3. After 5 minutes of cooling 0.5 µl 10 mg/ml EtBr was added per 10 ml gel. 
4. An appropriate comb was placed in a sealed mould, and agarose was poured into 
the mould. 
5. The gel was allowed to cool for at least 20 minutes before the seal and the comb 
was removed. The gel was then placed in an electrophoresis chamber filled with 
0.5 x TBE buffer. 
6. The PCR products was mixed with 1 µl 6 x loading buffer/5 µl PCR product and 
applied to a well. 5 µl of marker (Kb+) was loaded into the wells flanking the 
samples. 
7. The gel was run at 110 V for 50 minutes prior to photographing in a UV 





(Gel electrophoresis, version 1.2, DNA methods, Department of medical microbiology, 




Automatic DNA sequencing 
 
Pre-sequencing: Purification of PCR-products from excess components. 
A PCR-reaction use primers, dNTPs and DNA polymerase to produce multiple copies of a 
specific DNA sequence. These components are able to influence the following sequencing 
reaction because they exist in large quantities in the PCR product mix. Several methods are 
available removing these compounds. In this study three different methods were used, two 
different purification kits and purification by the use of ExoSAP. 
 
Purification kits: 
Purification kits use spin-column technology with selective binding properties of uniquely 
designed silica-membranes. The caption buffer (CP-buffer) effectively binds single or double 
stranded PCR-products as small as 50 bp, and removes 99.5% of the primers smaller than 40 
bp. Nucleic acid adsorb to the silica-gel membrane while contaminants pass through during 
centrifugation. The ethanol containing Wash Buffer efficiently washes away impurities. After 








Purification of PCR product by E.Z.N.A Cycle Pure Kit 
Procedure: 
1. The whole PCR-product volume was transferred to a clean 1.5 ml microfuge tube, 
and 6 volumes of CP-buffer were added. 
2. The sample was applied to a HiBind® DNA spin-column with a 2 ml collection 
tube and centrifuged at 13 000 rpm for 1 minute. 
3. Flow-through liquid was discarded, and the column was washed by adding 750 µl 
Wash Buffer and centrifuged at 13 000 rpm for 1 minute. 
4. Flow-through was discarded and the washing step repeated. 
5. The liquid was discarded and the empty column was centrifuged for 1 minute at 13 
000 rpm to dry the column matrix. (Critical for good DNA yields.) 
6. The HiBind® column was placed into a clean 1.5 ml microfuge tube. 
7. PCR-products were eluted by adding 30 µl TE-buffer directly onto the column 
matrix and centrifuged for 1 minute at 13 000 rpm.  
8. Concentration and purity of the DNA was measured using NanoDrop. 
 





DNA and Gel Band Purification Kit 
Procedure: 
1. A volume of up to 100 µl was transferred to a clean 1.5 ml eppendorftube, and 500 
µl Capture Buffer type 2 was added to the sample and mixed thoroughly. 
2. The Capture Buffer type 2-sample mix was loaded onto a GFX® MicroSpin 
column assembled with a collection tube. 
3. The column was spun for 30 seconds at 13 000 x g, and flow-through liquid was 
discarded. 
4. 500 µl Wash Buffer type 1 was added to the column, and spun for 30 seconds at 




5.  Flow-through liquid was discarded and the column transferred to a clean 1.5 ml 
eppendorftube. 
6. 10-50 µl Elution Buffer type 4 was added directly onto the centre of the membrane 
in the column, and the sample was incubated for 1 minute at room temperature. 
7. The sample was spun at 13 000 x g for 1 minute to recover the purified DNA. 
8. Concentration and purity of the DNA was measured using NanoDrop. 
 
Purification of PCR product by the use of ExoSAP 
This purification method removes the excess primers, dNTPs and DNA polymerase with the 
use of two hydrolytic enzymes, Shrimp Alkaline Phosphatase (SAP) and ExonucleaseI (Exo). 
SAP removes the remaining dNTPs and Exo removes the remaining primers. Both of the 
enzymes inactivates at 80°C for 15 minutes.  
Procedure: 
1. 1 µl ExoSAP-IT was added to 50 µl PCR product held on ice. New clean caps 
were placed on the PCR tubes. 
2. The samples were spun down and placed in the PCR-machine. The following PCR 
cycling program was used for the purification reaction: 
37°C 1 min 
37°C 60 min 
85°C 15 min 
  4°C ∞ 
3. The purified PCR-products were stored at -20°C. 
(Purification of PCR products by the use of ExoSAP, Version 1.0 Methodology, General 









The sequence reaction is carried out in both directions with both forward and reverse primers. 
Each of these reactions is performed by a single primed PCR using purified DNA as template.  
To ensure that the correct sequence is obtained all DNA sequencing reactions are performed 
bi-directionally. The sequencing reaction is based on DNA synthesis in the presence of 3’-dye 
labelled dideoxynucleotide triphosphate (ddNTPs, dye terminators) in addition to the standard 
deoxynucleotide triphosphates. The site of polymerisation is located at the 3’ OH group where 
dideoxynucleotides can be incorporated into a growing chain lacking this group and because 
of that terminates the DNA synthesis. In the automated fluorescent sequencing, fluorescent 
dye labels are incorporated into DNA extension products using 3’dye labelled terminators. 
During the sequencing reaction fragments with various lengths will be produced, each 
corresponding to the point at which a ddNTP was incorporated. After precipitating the Taq-
terminator amplicon, the samples are denatured and loaded onto the ABI PRISM® 3100 
Genetic Analyser that separate, detect, and analyse the fluorescent labelled DNA fragments 
using capillary electrophoresis. Molecules from the samples are injected into thin, fused-silica 
capillaries and the DNA fragments migrate towards the other end of the capillaries, with the 
shorter fragments moving faster than the longer fragments. As the fragments enter the 
detection cell, a laser beam detects the last incorporated base in each fragment. Since the four 
different ddNTPs are labelled with different dyes which emit light at different wavelength 
when excited by an argon ion laser, the laser is able to identify the A, C, G and T order and 
thereby the complete sequence of the DNA. DNA sequencing results were analyzed using the 
computer programs EditSeq and SeqMan (DNA Star from Lasergene). 
Procedure: 
1. The ABI PRISMTM BigDye® Terminator v3.1 Cycle Sequencing Kit was used for 
the cycle sequencing. The reaction for each template contained the following 
reagents (with A, C, G and T in one tube): 
BigDye 3.1    1 µl 
Template (30-300 ng)  3-6 µl 




Primer (2 pmol/µl)   1.6 µl 
ddH2O     up to 20 µl 
Total volume    20 µl 
2. The reactions were mixed in PCR tubes held on ice and placed in the PCR 
machine. The following PCR cycling parameters was used for the sequencing 
reaction: 
96°C for 1 minute 
25 cycles: 
 96°C for 10 seconds 
 50°C for 5 seconds 
 60°C for 4 minutes 
4°C until the samples are removed from the machine.  
 
Precipitation of the terminator reaction and the DNA-sequencing (ABI PRISM® 3100 
Genetic Analyzer, Applied Biosystems) were performed at the Sequencing Lab Unit, UiT. 
The nucleotide sequence is analyzed automatically and the result is presented as an 
electropherogram. The sequence is stored in the four-letter code for computer analysis. For 
further references, and detailed description of preparations of gels, running of samples, data 
collection software, instrument hardware and Macintosh maintenance; see BigDye Terminator 
v3.1 Cycle Sequencing Kit Protocol (2002): 
http://docs.appliedbiosystems.com/pebiodocs/04337035.pdf 
 
Isolation of RNA from bacterial cells 
When analysing RNA it is important that they represent the in vivo gene expression in a 
bacteria as truly as possible. A combination of two separate events is able to greatly affect the 
gene expression profile. The first is that the half-life of bacterial RNA is very short and they 
are enzymatically degraded within few minutes. This results in loss or reduction of many 




handling and processing of the bacterial cells before lysis. RNA should be stabilized in vivo, 
since most changes in the gene expression profile occur during or directly after the harvesting 
of bacterial cells. This ensures reliable gene expression analysis. RNAprotect® Bacteria 
Reagent stabilizes RNA before bacterial cells are lysed. Released RNA can then be purified 
with either RNeasy Mini Kit or RNeasy Midi Kit.  
 
Enzymatic lysis of bacteria by Qiagen RNAprotect® Bacteria Reagent  
RNAprotect® Bacteria Reagent stabilizes the RNA before bacterial cells are lysed. This 
ensures that the cells gene expression profile is not disturbed and allows efficient disruption. 
The reagent prevents both RNA transcripts degradation and induction of genes. Two volumes 
of RNAprotect Bacteria Reagent are added directly to one volume of bacterial culture 
providing immediate stabilization of RNA. The bacterial cells are then lysed to release RNA. 
Procedure:  
1. 2-3 single colonies were inoculated in 5 ml LB-broth overnight at 37°C in ambient 
air with agitation (150) rpm. 
2. 100 µl of the overnight culture was transferred into 30 ml LB-broth in Erlenmeyer 
bottles and incubated at 37°C with agitation (200 rpm) until O.D600nm reached 0.5-
0.7.  
3. 1 ml bacterial culture was transferred to an Eppendorftube, and 500 µl RNA 
protect was added. The tube was immediately vortexed for 5 seconds and 
incubated at room temperature for 5 minutes. 
4. The tube was centrifuged for 10 minutes at 10 000 rpm (5000 x g) in an Eppendorf 
fuge.  
5. The supernatant was decanted and residual supernatant was removed by gently 
dabbing the inverted tube once on a paper towel. 
6. Bacteria pellet was kept on dry ice until the next step was started. 
7. 200 µl TE-buffer containing lysozym (1 mg/ml) was added and the tube vortexed 
for 10 seconds. 
8. The suspension was incubated for 10 minutes at room temperature and mixed 




9. 700 µl RLT-buffer containing 28 µl dtt per 700 µl RLT-buffer was added and 
vortexed vigorously. 
10. 500 µl 96% EtOH was added and mixed by pipetting or shaken vigorously. 
 
(RNAprotect® Bacteria Reagent Handbook Protocol 1) 
 
RNA extraction and purification by RNeasy® Mini Kit  
The released RNA is purified using RNeasy Mini Kit. The method combines the selective 
binding properties of a silica-based membrane with the speed of microspin technology. Up to 
100 µg RNA longer than 200 bp are allowed to bind to the silica-membrane with a specialized 
high-salt buffer system. The total RNA binds to the membrane and contaminants are 
efficiently washed away. RNAs shorter than 200 nucleotides are selectively excluded which 
provides an enrichment of mRNA. The resulting high-quality RNA is suitable for use in 
several downstream applications as quantitative real-time RT-PCR and northern, dot, and slot 
blotting. 
Procedure: 
1. 700 µl lysate was added to an RNeasy Mini spin column placed in a 2 ml 
collection tube and centrifuged for 15-20 seconds at 8000 x g (≥10 000 rpm). 
2. Flow-through was discarded and step 1 repeated. 
3. 350 µl RW1-buffer was added, the tube centrifuged 15-20 seconds at 8000 x g and 
the flow-through was discarded. 
4. 80 µl incubation mix was added to the spin column and incubated for 15 minutes 
at room temperature. 
5. 350 µl RW1-buffer was added and incubated for another 5 minutes at room 
temperature and centrifuged for 15-20 seconds at 8000 x g. 
6. The spin column was placed in a new 2 ml collection tube, 500 µl RPE-buffer was 
added and the tube centrifuged for 15-20 seconds at 8000 x g to wash the column 
matrix. 




8. The spin column was placed in a new 1.5 ml Eppendorftube. 30 µl RNase free 
water was added to elute the RNA by centrifugation for 1 minute at 8000 x g. 
9. The tube was kept on ice and the sample was divided in pre-marked 
Eppendorftubes and quickly frozen at -70°C for storage.  
10. 3-5 µl was kept to measure RNA concentration and purity by using the NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies, Inc.).  
 
(RNAprotect® Bacteria Reagent Handbook Protocol 7) 
 
 
Measurement of DNA and RNA concentration with NanoDrop 
ND-1000 Spectrophotometer, Thermo Technologies 
The NanoDrop ND-1000 spectrophotometer use a patented sample retention system holding 1 
µl of sample not needing traditional containment devices such as cuvettes and capillaries. The 
sample is held in place between two optical surfaces using fiber optic technology and surface 
tension defining the pathlength in a vertical orientation. During each measurement cycle 
sample is assessed at both a 1 mm and 0.2 mm path providing extensive dynamic range (2 
ng/µl to 3700 ng/µl for dsDNA). This eliminates the need to perform dilutions or to make 
assumptions regarding sample concentration. Interference caused by incident light and 
transmitting light passing through containment walls of traditional cuvettes, microcell 
cuvettes and capillaries are removed with the direct coupling to the optics. Total measurement 
cycle time, including preparation and removal of the sample, is approximately 30 seconds. 
Procedure: 
1. 1-2 µl of ddH2O was loaded onto the lower optical surface. The lever arm was 
closed and tapped a few times to bathe the upper optical surface. The lever arm 
was then lifted and both optical surfaces were wiped off with a Kimwipe. 




3. The spectrophotometer was initialized by placing 1 µl ddH2O onto the lower 
optical surface, lowering the lever arm and then select “initialize” in the NanoDrop 
software. After initialization was completed (10 sec) both optical surfaces were 
cleaned with a Kimwipe. 
4. A blank measurement was performed by loading 1 µl ddH2O or buffer selecting 
“blank”. When the blank was completed both optical surfaces were cleaned. 
5. The nucleic acid sample was measured by loading 1 µl and selecting “measure”. 
Once the measurement was completed both of the optical surfaces were cleaned.  
6. After all the samples had been measured the optical surfaces were washed as 
described in step 1. 
 
(Current Protocols in Molecular Biology Volume 1, Quantitation of DNA and RNA with 
Absorption and Fluorescence Spectroscopy, A.3D.9, Supplement 76: 
http://www.nanodrop.com/Science.aspx?Cat=Protocols) 
 
cDNA synthesis of RNA  
This PCR cycle reaction kit allows the reverse transcription of total RNA into single stranded 
cDNA suitable for quantitative PCR applications like real-time RT-PCR. 
Procedure: 
1. The RNA was diluted to a final concentration of 40 ng/µl with RNase free water. 
2. The cDNA synthesis was performed with one sample per RNA extract, and each 
reaction had a total volume of 20 µl. 10 µl cDNA Mastermix + 10 µl RNA (40 
ng/µl). 
3. To check for DNA contamination in the qRT-PCR one sample per RNA extract 
had water instead of the reverse transcriptase in the cDNA Mastermix. 
cDNA Mastermix for 1 sample of 20 µl: 
10x RT buffer    2.0 µl 




10x RT random primers  2.0 µl 
Reverse transcriptase (ddH2O) 1.0 µl 
RNase inhibitor   1.0 µl 
Nuclease free H2O   3.2 µl 
Total volume    10.0 µl 
 
4. The reverse transcription PCR program: 
Step  Temperature  Time 
1  25°C   10 min 
  Step 2  37°C   120 min 
  Step 3  85°C   5 sec 
  Step 4    4°C   Max 1 hour, freeze at -20°C immediately 
5. The samples were frozen at -20°C immediately. 
 
(High-Capacity cDNA Reverse Transcription Kits Protocol, Applied Biosystems 2006)  
 
Quantitative Real Time PCR (qRT-PCR) 
This strategy for relative quantitation of gene expression allows quantifying differences in the 
expression level of a specific gene between different samples (isolates). Output data is 
expressed as a fold-change or a fold-difference of expression levels. RT-PCR gives the ability 
to monitor the progress of the PCR as it occurs. Data is collected during the reaction process 
instead of at the end of the reaction. Reactions are characterized by the point in time during 
cycling when amplification of target is first detected rather than the amount of target 
accumulated after a fixed number of cycles. The higher the starting copy number of the 
nucleic target, the sooner a significant increase in fluorescence is observed. There are two 
types of chemistries available to detect PCR products using Sequence Detection Systems 




Green I dye chemistry. In this study the TaqMan chemistry using a fluorogenic probe, 
enabling the detection of a specific PCR product as it accumulates during PCR cycles, was 
used. 
The stepwise process starts with construction of an oligonucleotide probe containing a 
reporter fluorescent dye on the 5’ end and a quencher dye on the 3’ end. If the target sequence 
is present, the probe anneals downstream form one of the primer sites and is cleaved by the 5’ 
nuclease activity of Taq DNA polymerase as this primer is extended. This cleavage of the 
probe, separates the reporter dye from the quencher dye, increasing reporter dye signals, and 
removes the probe from the target strand, allowing primer extension to continue to the end of 
the template strand. Additional reporter dye molecules are cleaved from their respective 
probes with each cycle, resulting in fluorescence intensity proportional to the amount of 
amplicon produced. 
Procedure: 
1. The 96-well plate was set up with each cDNA synthesis sample as a duplicate. 
This generated a total of 8 qRT-PCR samples per cDNA sample, 4 samples for the 
gene of interest and 4 samples for the normalization gene. A mastermix control for 
each gene was also put up where the cDNA was replaced with water. 
2. The cDNA samples were diluted 1:10, and each of the qRT-PCR reactions had a 
total volume of 25 µl consisting of 20 µl mastermix and 5µl diluted cDNA. 
qRT-PCR mastermix 60 x primer/probe assay for 20 samples: 
60 x primer/probe stock  8.5 µl 
Nuclease free water   141.5 µl 
2 x Taqman Universal mastermix 250 µl 
Total volume    400 µl 







Chromosomal analysis by Pulsed-Field Gel Electrophoresis 
(PFGE) 
Pulsed-Field Gel electrophoresis (PFGE) is a technique for resolving large chromosomal 
DNA fragments. Macrorestricted linear bacterial DNA fragments from 100 bp to 10 Mbp can 
be separated. The method basically involves electrophoresis in agarose where two electrical 
fields are applied alternately at different angles for defined time periods. Activation of the 
first electrical fields causes the coiled molecules to be stretched in the horizontal plane and 
start moving through the gel. Interruption of this field and application of the second field, 
force the molecules to move in the new direction. Since there is length dependent relaxation 
behaviour when a long-chain linear molecule undergoes conformational changes in an 
electrical field, the smaller molecule, the quicker it realigns itself with the new field and is 
able to continue to move through the gel. Larger molecules take longer time to realign. In this 
way, smaller molecules draw ahead of larger molecules draw ahead of larger molecules and 
separate according to size.  
PFGE involves the embedding of bacteria in agarose plugs to protect the chromosomes from 
fragmentation due to mechanical damage. The cells are lysed by treatment of the plugs with 
cell-lysis enzymes such as lysozym and lysostaphin. Extensive washing removes 
contaminants. The remaining genome is then digested in situ with restriction enzymes that 
have few recognition sites resulting in a relatively small number of restriction fragments (10-
30). The separation of restriction fragments is affected by agarose concentration, buffer 
concentration, buffer temperature, initial and final switch times, voltage, total electrophoresis 
run time and field angle. 
 
Preparation of PFGE plugs 
Procedure: 
1. One single colony was inoculated in 5 ml BHI-medium and incubated over night at 




2. 50 µl of the culture was transferred to 5 ml BHI and incubated for another 4 hours 
at 37°C, shaking (250 rpm). The bacterial cells should be in exponential growth 
when harvested. 
3. The culture was transferred to a 15 ml Falcon tube and centrifuged at 3500 rpm for 
10 minutes. 
4. The supernatant was discarded and the cell pellet was resuspended in 1 ml cold 
PIV-buffer. 
5. 495 µl of the suspension was transferred to a new Eppendorftube. 5 µl of lysozym 
(100 mg/ml) was added and the suspension was mixed well by vortexing and 
equilibrated at 50°C on a water bath. 
6. 500 µl of 2 % LMP-agarose equilibrated at 50°C was added, and the 
bacteria/agarose solution was mixed properly. 
7. The mixture was then cast into a plug mould. 
8. The plug was incubated at 4°C for 15 minutes to solidify, and transferred to a T-
tube containing 2 ml lysisbuffer. 
9. The plug was then incubated for another 2 hours at 37°C for 2 hours with careful 
slow shaking. 
10. The lysisbuffer was removed and the plug washed with 1 ml ddH2O for 15 
minutes. 
11. The plug was incubated in 1 ml of ESP-buffer containing 50 µg/ml proteinase K-
solution overnight at 50°C. 
12. The plug was washed in 1 ml TE-buffer for 30 minutes at room temperature. 
Repeated twice. 
13. The plug was transferred to a new tube containing 1 ml TE-buffer (with 50 µM 
thiurea) and stored at 4°C for further use. 
 
Xba1 digestion and electrophoresis 
Procedure: 
1. A thin slice of the plug, approximately 1 mm, was cut off and transferred to an 
Eppendorftube.  




3. The following restriction enzyme mix was made: 
XbaI mixture for 12 plugs: 125 µl x 12 =  1500 µl 
Buffer 2 (10x): 12.5 µl x 12 =     150 µl 
20 U XbaI: 20 U x 12 = 240 U → 240:20 U/µl = 12 µl 
BSA (100x):         15 µl 
ddH2O:      1323 µl 
4. 125 µl of the restriction enzyme mix was added to each plug before incubation at 
37°C overnight.  
5. The plug was then washed with TE-buffer for 4 x 30 minutes. 
6. 1 % agarose was dissolved in 100 ml 0.5 x TBE-buffer by boiling, and equilibrated 
at 50°C in a water bath. 
7. The gel equipment was prepared. Plugs were placed onto the tip of the gel comb, 
and mounted directly into the gel by inserting the comb before pouring the 
agarose. The gel solidified for 30 minutes at room temperature. 
8. The electrophoresis chamber was filled with 1.8-2 liters of TBE-buffer. Circulation 
and cooler was then turned on to let the buffer cool down to 12°C. 
9.  When the gel had solidified the comb was removed and the gel released from the 
mould. All excess agarose was carefully removed. 
10. The support plate was pressed down in the frame in the electrophoresis chamber, 
and the following parameters was run in the program: 
Pulse time:  1-20 s 
Total run time: 21 h 
Voltage:  6.0 V/cm = 200 V 
Angle:   120° 
Buffer temperature: 12°C 




11. When the program was finished, the gel was stained with EtBr (500 ml H2O + 50 
µl EtBr) for 20 minutes, destained in ddH2O for 40 minutes and photographed in a 
UV transilluminator at 260 nm.  
  
(Methods UiT)  
 
Isoelectric focusing (IEF)  
 
Isoelectric focusing (IEF) is an electrophoretic method that separates proteins according to 
their isoelectric points (pI). This technique is dependent on the presence of a pH gradient. 
Under the influence of an electric field in a pH gradient the protein will migrate to the 
position where its net charge is zero. A protein with a positive net charge will migrate toward 
the cathode, becoming less positively charged the further it moves through the gradient until it 
reaches its pI. A protein with a negative net charge will migrate towards the anode and 
become less negatively charged until it reaches its pI. The focusing effect of this method is 
that proteins are concentrated at their pIs and the separation is precise with very small charge 
differences. If a protein diffuse away from its pI it immediately gains charge and migrates 
back to its isoelectric point. The degree of resolution in IEF is determined by the electric field 
strength performed at a high-voltage greater than 1 000 V.  
Procedure: 
1. One single colony was inoculated in 5 ml LB-broth and incubated over night at 
37°C with agitation (200 rpm). 
2. The culture was transferred to a 15 ml Falcon tube kept on ice and centrifuged at 
4000 rpm for 10 minutes at 4°C. 
3. The supernatant was discarded and the pellet was resolved in 1 ml 10 mM Tris-
HCL pH 7.0 (buffer). 
4. The sample was sonicated on ice 2 x 30 seconds by 25% amplitude, pulsing 1 
second on/1 second off, and inspected visually for “clearing” of the solution. 




6. The supernatant was collected and kept on ice. 
7. The Multiphore II electrophoresis unit was connected to the MultiTemp II 
thermostatic circulator and the temperature was set to 10°C. 
8. The gel was cut into right size according to the sample numbers and the protecting 
films removed. 
9. A few ml of kerosene was loaded onto the cooling plate and the gel was positioned 
on the plate making sure no air bobbles was trapped under it. 
10. Electrode strips were soaked evenly in 2-3 ml anode (+) and cathode (-) electrode 
solutions and applied to the long edges of the gel. 
11. Pre-run the gel for 15 minutes, with the right running conditions. 
12. An applicator strip (IEF/SDS) was used to load 20 µl of the samples on the gel 
depending on the expected pI-value. 
13. The program was started again and these were the running conditions used: 
pH range 3.5-9.5 
Voltage (V) 1500 V 
Current (mA) 50 mA 
Power (W) 30 W 
Time (h) 1.5 h 
14. After the program finished the gel was removed and placed in a tray. 
15. Nitrocefin was prepared and added to the gel for staining of the proteins.  
Nitrocefin solution: 
Tris-HCL (10mM, pH 7.95) 19 ml 
DMSO   1 ml 
Nitrocefin (0.5 g/l)  0.010 g 
Total volume   20 ml 
16. The gel was visually inspected for red bands during staining. Pictures were taken 




17. Marker bands were measured on the picture to plot the values in a pI-curve, 
measuring and reading their pI-values from the marker pI-curve. 
 
(Protocol for isoelectric focusing of β-lactamases, Department of Microbiology, University 




Cloning is a technique based on the isolation and multiplying of target DNA fragments, like 
genes, by PCR. The multiplied genes are ligated into an expression vector and then 
transformed into a new bacterium expressing only this DNA fragment. This method is a 
helpful tool testing the properties of a gene expressing resistance against antibiotics.   
 
Isolation of plasmids with E.Z.N.A Plasmid Midiprep Kit 
The Plasmid Midiprep kit combines the power of HiBind® technology with the time tested 
consistency of alkaline-SDS lysis of bacterial cells to deliver high quality DNA. The columns 
bind reversibly to DNA or RNA under certain optimal conditions allowing proteins and other 
contaminants to be removed. Omega Bio-Tek’s midi-columns facilitate the binding, washing, 
and elution steps enabling multiple samples to be processed simultaneously. Yields vary 
according to plasmid copy number, but 50 ml overnight culture can typically produce 100-200 
µg high copy plasmid DNA. Purified DNA is suitable for most downstream applications 
including automated fluorescent DNA sequencing, restriction endonuclease digestion, and 
other manipulations.  
Procedure:  
1. One single bacterial colony was inoculated in 30 ml LB medium (with 100 µg/ml 
ampicillin or 50 µg/ml kanamycin) and incubated over night at 37°C with an 




2. The suspension was centrifuged at 4000 x g for 10 minutes at room temperature 
and the medium was discarded. 
3. Cell pellet was resuspended in 2.25 ml Solution I/RNase A. 
4. Cell suspension was then transferred to a 15-30 ml centrifuge tube. 2.25 ml of 
solution II and 50 µl of OB Protease Mixture were added to the suspension and 
incubated at room temperature for 3-5 minutes. 
5. 3.2 ml Solution III was added and the tube gently mixed until a white flocculent 
precipitate formed.  
6. The suspension was centrifuged at 12 000 rpm for 10 minutes at 4°C to pellet the 
cellular debris and genomic DNA. 
7. 1 ml Equilibration Buffer was added into a HiBind®DNA Midi column, pre-
inserted in a 15 ml collection tube, and was incubated for 4 minutes at room 
temperature to equilibrate the membrane. The tube was then spun at 3000 rpm for 
3 minutes. 
8. The clear supernatant was carefully aspirated and 3.75 ml was added to a clean 
equilibrated HiBind®DNA Midi column assembled in a 15 ml collection tube. 
9. The tube was centrifuged at 5250 rpm for 5 minutes. 
10. Flow-through was discarded and step 8 and 9 was repeated until all the cleared 
lysate had been passed through the column. 
11. 3.5 ml Buffer HB was added to the column and centrifuged at 5250 rpm for 5 
minutes. Flow-through was discarded.  
12. The column was washed by adding 3.5 ml of DNA Wash Buffer and spun at 5250 
rpm for 5 minutes. Flow-through was discarded. 
13. The column was then washed with 3.5 ml absolute ethanol and centrifuged at 5250 
rpm for 5 minutes. Flow-through was discarded. 
14. An additional centrifugation at 5250 rpm for 10 minutes was performed to dry the 
empty column matrix.  
15. The column was placed in a new clean 15 ml centrifuge tube and 0.5 ml DNA 
Elution Buffer was added directly onto the column matrix.  
16. After 2 minutes of incubation at room temperature the tubes was centrifuged at 
5250 rpm for 5 minutes to elute the DNA. 





Isolation of plasmids with E.Z.N.A Plasmid Miniprep Kit 
The Plasmid Miniprep kit combines the power of HiBind® technology with the time tested 
consistency of alkaline-SDS lysis of bacterial cells to deliver high quality DNA. The columns 
bind reversibly to DNA or RNA under certain optimal conditions allowing proteins and other 
contaminants to be removed. HiBind® mini columns facilitate the binding, washing, and 
elution steps enabling multiple samples to be processed simultaneously. Yields vary 
according to plasmid copy number, but 1.5 ml overnight culture can typically produce 8-12 
µg high copy plasmid DNA. Purified DNA is suitable for most downstream applications 
including automated fluorescent DNA sequencing, restriction endonuclease digestion, and 
other manipulations.  
Procedure: 
1. One single bacterial colony was inoculated in 5 ml LB medium (with 100 µg/ml 
ampicillin or 50 µg/ml kanamycin) and incubated over night at 37°C with an 
agitation of 250 rpm. 
2. The suspension was centrifuged for 1 minute at 10 000 x g at room temperature 
and the medium was discarded. 
3. Cell pellet was resuspended in 250 µl Solution I/RNase A. 
4. 250 µl solution II was added and the tube gently mixed by inverting and rotating 
the tube several times to obtain a clear lysate. 
5. 350 µl solution III was then added and mixed immediately by inverting the tube 
several times until a flocculent white precipitate formed. 
6. The suspension was centrifuged at 13 000 x g for 10 minutes at room temperature 
in a mini centrifuge from. 
7. The clear supernatant was carefully aspirated, and added into a clean HiBind® 
Miniprep Column assembled in a 2 ml collection tube.  
8. To completely pass the lysate through the column the tube was centrifuged at 
13 000 x g for 1 minute at room temperature. 
9. Flow-through liquid was discarded and 500 µl Buffer HB was added to wash the 
column. The sample was centrifuged at 13 000 x g for 1 minute at room 




10. Flow-through liquid was discarded and 700 µl DNA Wash Buffer was added, and 
the tube centrifuged at 13 000 x g for 1 minute to wash the column. 
11. The empty column was centrifuged for 2 additional minutes at 13 000 x g to dry 
the column matrix. 
12. The column was placed into a clean 1.5 ml eppendorftube and 50 µl DNA Elution 
Buffer was added directly onto the column matrix and centrifuged for 1 minute at 
13 000 x g to elute DNA. 
13.  Concentration and purity of the DNA was measured using NanoDrop. 
 
 
pGEM®-T Easy Vector Systems 
The pGEM®-T Easy vector is a linearized high-copy number vector with T-overhangs at the 
insertion site improving the efficiency of ligation of PCR products. The vector contains 
numerous restriction sites within the multiple cloning regions.   
Ligation 
Procedure: 
1. PCR was run on the desired gene inserts, controlled with gel electrophoresis and 
purified with a purification kit. DNA concentration and purity was measured using 
NanoDrop ND-1000. 
2. The appropriate amount of PCR product (insert) to include in the ligation reaction 
was calculated using the following equation: 
ng of vector х kb size of insert  х  insert:vector molar ratio  =  ng of insert 
 kb size of vector 
 
50 ng vector х 1.1 kb insert х 3 = 55 ng insert 





3. The pGEM®-T Easy Vector tube was briefly centrifuged to collect the contents at 
the bottom of the tube. 
4. The ligation reaction was set up as described below: 
Ligation mix: 
2x Rapid Ligation Buffer, T4 DNA Ligase 5 µl 
pGEM-T Easy Vector (50 ng)  1 µl 
PCR product (55 ng)    X µl 
T4 DNA Ligase (3 Weiss units/µl)  1 µl 
Nuclease free water (up to 10 µl)  X µl 
Total volume     10 µl  




1. Two LB-plates with treated with 14 µl IPTG and 50 µl X-gal was prepared and 
equilibrated to room temperature. 
2. 2 µl of the ligation mix was transferred to a new clean Eppendorftube held on ice.  
3. A tube of frozen DH5α high efficiency competent cells was put on ice until just 
thawed (5-15 minutes). Cells were mixed gently by flicking the tube. 
4. 50 µl of cells was carefully transferred into the tube with the ligation mix.  
5. The tube was gently flicked to mix the content and incubated on ice for 20 min. 
6. The cells were heat-shocked for 50 seconds in a water bath at exactly 42°C. 
7. The tube was immediately returned to the ice for 2 minutes. 
8. 950 µl SOC-medium with room temperature was added to the tube and the 




9. 100 µl transformation culture was plated onto the prepared LB-plates, and 
incubated at 37°C overnight (16-24 hours). 
 
pBK-CMV Phagemid Vector Cloning Kit 
The pBK-CMV phagemid vector is a cloning vector derived from a high-copy-number pUC-
based plasmid. This vector allows expression in both eukaryotic and prokaryotic systems. 
Prokaryotic expression is driven by the lac promoter, which is repressed in the presence of X-
gal and IPTG. Kanamycin resistant colonies containing vector with insert will be white and 





Cutting of the pBK-CMV and the ampC gene with restriction enzymes EcoR1 and Not1 
Procedure:  
1. The pBK-CMV plasmid and the desired insert were prepared for the ligation 
reaction by cutting their DNA with EcoR1 and Not1 restriction enzymes. 
2. Gene cutting mastermix contents: 
Purified PCR product (insert) and plasmid: 
Purified PCR product/plasmid (30 µg) 30/х µl 
EcoR1 Buffer (NEB)    10 µl 
ddH2O      51/х µl 
EcoR1 restriction enzyme   4 µl 
Not1 restriction enzyme   4 µl 




Total volume     100 µl 
3. The tubes with the cutting mixes were incubated at 37°C for 2 hours. 
4. After the cutting all samples were run in 1% agarose gel electrophoresis with 
Cybersafe as the fluorescence marker instead of EtBr to protect the DNA. 
5. After the electrophoresis was done the cut fragments were purified.  
 
Purification of the cut fragments with E.Z.N.A Gel Extraction Kit 
The Gel Extraction kit uses the HiBind® technology to recover DNA bands in the size range 
50 bp to 40 kb from all grades of agarose gel. The yield is more than 85% of the total product. 
DNA bands of interest is excised from the gel, dissolved in Binding Buffer, and applied to a 
HiBind® DNA spin column. The HiBind® matrix specifically, but reversibly, binds to DNA 
or RNA under certain optimal conditions so that proteins and other contaminants can be 
removed. DNA is eluted with Elution Buffer and ready for other applications after a rapid 
washing step. The product is then suitable for ligation, PCR, sequencing, restriction digestion, 
or various labelling reactions.   
Procedure: 
1. Agarose gel electrophoresis was performed to fractionate the DNA fragments. 
2. After adequate separation of bands had occurred, the DNA fragment of interest 
was carefully excised using a wide, clean, sharp scalpel and UV-light. 
3. The appropriate volume of the gel slice was determined by weighing it in a clean 
1.5 ml Eppendorftube. An equal volume of Binding Buffer (XP2) was added, and 
the mix incubated at 55°C-60°C for 7 minutes or until the gel had completely 
melted. The tube was vortexed every 2-3 minutes. 
4. A HiBind® DNA Mini Column was placed in a 2 ml collection tube. 
5. 700 µl of the DNA/agarose solution was applied to the column and centrifuged at 
10 000 x g for 1 minute at room temperature. 
6. Liquid was discarded and the column was placed back in the collection tube. 
7. 300 µl of Binding Buffer (XP2) was added to the column and centrifuged at 




8. 700 µl of SPW Wash Buffer was added to wash the column and centrifuged at 
10 000 x g for 1 minute at room temperature.  
9. Liquid was discarded and the empty column was centrifuged for 2 additional 
minutes at ≥ 13 000 x g to dry the column matrix. 
10. The column was placed in a new clean Eppendorftube and 30 µl of Elution Buffer 
was added directly onto the column matrix and incubated for 1 minute at room 
temperature. To elute DNA the tube was centrifuged at ≥ 13 000 x g for 1 minute. 
11. Concentration and purity of the DNA was measured using NanoDrop. 
 
Ligation of ampC gene into pBK-CMV 
Procedure: 
1. The appropriate amount of PCR product (insert) to include in the ligation reaction 
was calculated using the following insert-to-vector molar ratio equation: 
ng of vector х kb size of insert  х  insert:vector molar ratio  =  ng of insert 
 kb size of vector 
 
50 ng vector х 1.2 kb insert х 3/1 = 40 ng insert 
4.5 kb vector   
 
2. To prepare the ligation reaction the following components were mixed in an 
Eppendorftube: 
pBK-CMV (50 ng)    x µl 
10 x T4 ligase buffer    2 µl 
T4 DNA ligase enzyme (400 000 U/ml) 1 µl 




ddH2O (up to 20 µl)    x µl 
Total volume     20 µl 
3. The ligation reaction was mixed gently and incubated for 10 minutes at room 
temperature. 
 
Transformation of the recombinant plasmid pBK-CMV into the recipient E. coli strain 
SNO3 
Procedure: 
1. E. coli SNO 3 was thawed on ice (5-15 minutes) and mixed gently by flicking the 
tube. 
2. 20 µl of the ligation mix and 0.5 µl of “clean” pBK-CMV were added carefully to 
the tube with 100 µl E. coli SNO 3 cells.  
3. The tube was gently flicked to mix the transformation suspension and incubated on 
ice for 20 minutes. 
4. The cells were heat-shocked for 50 seconds in a water bath at exactly 42°C. 
5. The tube was immediately returned to the ice for 2 minutes. 
6. 500 µl room tempered SOC-medium was added to the tube, and the suspension 
was incubated for 1 hour at 37°C with slow shaking (150 rpm). 
7. 100 µl transformation reaction culture was plated onto LB-kanamycin plates (50 





PCR amplification control of insert 
The presence and size of the DNA insert in pBK-CMV may be determined and controlled by 





1. Each of the 5 transformed single colonies picked were inoculated in an 
Eppendorftube containing 20 µl ddH2O. 
2. All samples were streaked onto LB-kanamycin patch plates (50 µg/ml) for future 
reference and incubated at 37°C overnight (16-24 hours). 
3. The cell suspensions were then boiled at 100°C for 10 minutes to lysate the cells 
and release DNA. 
4. The tubes were centrifuged at 13 000 rpm for 1 minute to form a pellet. 
5. The tubes were immediately placed on ice and supernatant was transferred to new 
clean Eppendorftubes. 
6. A PCR amplification reaction was prepared containing the following components: 
Reddymix x 2   10 µl 
ddH2O    7.6 µl 
Primer forward (2 pmol/µl) 0.2 µl
*See table 3.5. 
Primer reverse (2 pmol/µl) 0.2 µl
*See table 3.5. 
Templat   2.0 µl 
Total volume   20 µl 
7. The PCR was performed using the following cycling parameters: 
1 cycle: 
 94°C for 4 minutes 
 50°C for 2 minutes 
 72°C for 2 minutes 
30 cycles: 
  94°C for 30 seconds 




  72°C for 1 minute 
72°C for 5 minutes 
4°C until the samples are removed from the machine.  
8. The PCR-products was analyzed to determine insert sizes using standard 1% (w/v) 
agarose gel electrophoresis. The expected size of the PCR product should be 167 
bp plus the size of the insert. 
 
Sequencing of the plasmid insert 
After the analyzing of the insert verified that the product had the right fragment size, the 
plasmid with insert was sequenced. 
Procedure: 
1. The reaction for each plasmid template contained the following reagents: 
BigDye 3.1    1 µl 
Template (100-300 ng dsDNA) 3-6 µl 
BigDye sequencing buffer (5x) 2.5 µl 
Primer (2 pmol/µl) *See table 3.5. 1.6 µl 
ddH2O     up to 20 µl 
Total volume    20 µl 
 
3. The following PCR cycling parameters was used for the sequencing reaction: 
96°C for 5 minutes 
30 cycles: 
 96°C for 10 seconds 




 60°C for 4 minutes 
4°C until the samples are removed from the machine.  
 
Susceptibility testing by Etest 
Etest is a quantitative method to confirm bacteria susceptibility against antibiotics. This test 
determines the MIC (Minimum Inhibitory Concentration) value of the actual strain, 
establishing the lowest concentration of an antibiotic inhibiting visible growth of bacteria. A 
thin plastic strip is covered with a continuous antimicrobial gradient of an antibiotic on one 
side and a number scale on the other. The antibiotic is immediately released into the agar 
when applied to an inoculated agar plate forming a stable continuous gradient of antibiotic 
concentrations underneath the strip. When the bacterial growth has become visible after 
incubation an ellipse formed inhibition zone is seen centred along the strip. The MIC value is 
red from the scale (µg/ml) where the ellipse edge intersects the strip. MIC measures are 
accurate and reproducible.  
Procedure: 
1. The E-test strips were taken out of the -20°C freezer and allowed to achieve room 
temperature before use (1 hour). 
2. Colonies from an overnight green agar plate with 100 µg/ml ampicillin were 
selected and inoculated in a 0.9 % NaCl to adjust the suspension to match the 0.5 
McFarland turbidity standards. 
3. A sterile non-toxic swab was dipped into the bacterial suspension, and excess fluid 
was removed by pressing the swab against the inside wall of the test tube. The 
surface of a MH-agar plate was swabbed by the use of a rotator to ensure an even 
distribution of the inoculum. 
4. The surface was allowed to dry for 15 minutes. 
5. Two (small MH plate) to six (large MH plate) E-test plastic strips were applied 
onto the inoculated agar surface (Simlex C76 robot, vacuum pen, tweezers), 
ensuring that no air bobbles got trapped under the strip. 
6. The plates were incubated at 37°C for 16-18 hours, before reading the MIC values 




MIC interpretive standards (µg/ml) for E. coli can be found in Table 3.11. The breakpoints are 
from AFAs breakpoints Enterobacteriaceae ISBN 978-82-92345-11-5 Sensitive (S) ≤ and 




Table 3.11 MIC interpretative standards 
(µg/ml) 
Antimicrobial agent S ≤ R > 
Ampicillin 0,5 8 
Amoxicillin/clavulanic acid 0,5 8 
Piperacillin/tazobactam 8 16 
Cefoxitin
1
 2 4 
Cefuroxime 0,5 8 
Cefpodoxime 1 2 
Cefotaxime 1 2 
Aztreoname 1 8 
Meropeneme 2 8 
Ceftazidime 1 8 
 
(Microbiological Methods version 2.0, Determination of MIC-values by Etest, Department for 
microbiology and virology, IMB.)  
 














Sequencing of the control and gene coding region of the ampC 
gene 
Sequencing was performed to analyse the chromosomal ampC genes for mutations in the 
control and gene coding region. Detection of promoter mutations was based on the nucleotide 
sequence, while detection of mutations in the gene coding region was based on the nucleotide 
mutations leading to a change in the amino acid sequence. All cephalosporin resistant (n=55) 
and sensitive (n=10) isolates were sequenced. The sensitive isolates were sequenced as 
controls for natural variations in the amino acid sequence. E. coli K12 sequence functioned as 
the control strain for the nucleotide sequence alignment. A complete alignment of the 
promoter sequences can be found in APPENDIX 2. 
51 (91%) of the resistant isolates had mutations in the promoter regions. The changes 
included C→T mutations at position -42 (n=30, 54.5%), G→A mutations at position -18 
(n=30, 54.5%), TTGTCA→TTGACA changes in the -35 box (n=7, 12.7%) and 
TACAAT→TATAAT changes in the -10 box (n=4, 7.3%). Nine (16.4%) isolates had a single 
nucleotide insertion in the spacer regions between the -35 and -10 boxes, shifting their length 
of this region to the optimal 17 bp. These represents the most important and essential 
mutations for increased resistance against cephalosporins. Eighteen (32.7%) isolates had 
mutations in the attenuator region (+17 - +37).  In addition there were variable substitution 
mutations and spacer mutations at other positions in the promoter of the isolates. Twentyeight 
(50.9%) of the isolates with the C→T mutation at position -42, also contained mutations at 
position -88 (C→T), -82 (A→G), -18 (G→A) and -1 (C→T). Seven (12.7%) of the isolates 
with promoter mutations had an IS-element, IS911, between the -35 box and -10 box 
interrupting the promoter region. All these isolates had additional G→A mutations at position 
-28 and C→T mutations at position -73 in the promoter region. These isolates were selected 
for further genotypic studies to analyse clonal relatedness. Five (9.1%) of the resistant isolates 
had no mutations at any positions in the promoter. Strain K15-8 had no alterations in the 
promoter, but is identified with a large insertion sequence at position -17/-18 recognized as 




Amino acid sequence analysis revealed 4 (7.2%) isolates with interesting properties for 
further studies that did not possess any alterations in the promoter or an IS911 IS-element. 
One isolate, K41-64, showed no essential promoter mutations or special mutations in the gene 
coding region explaining its decreased susceptibility against cephalosporins. Three isolates, 
K33-24, K44-60 and K46-23, had no essential promoter mutations, but contained mutations in 
the gene coding region differing from the sensitive sequences that might be important to the 
increased resistance. 
These four isolates were chosen for further studies by cloning (see below). 




















Table 4.1. Molecular features of the promoter           
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Further analysis of isolates with the IS-element IS911 and isolates 
without promoter mutations 
Pulsed-Field Gel Electrophoresis (PFGE) 
XbaI digested DNA from the seven isolates carrying IS-element IS911, in front of the gene 
coding region, was examined by PFGE to establish a potential clonal relationship among 
them. Analysis showed that six isolates had identical band patterns on the gel, indicating a 
clonal relationship between these strains. The last strain had a band pattern that didn’t 
resemble the others indicating no clonal relationship to these strains (presented in Figure 4.1). 
 
 
Figure 4.1. PFGE of XbaI digested DNA from isolates carrying IS-element IS911. Lane 1: Low range 
PFGE marker, lane 2 and 3: K29-48, lane 4 and 5: K29-77, lane 6 and 7: K29-80, lane 8 and 9: K30-














Multi Locus Sequence Typing (MLST) 
To confirm that the six isolates with IS911 were clonally related to each other, and that the 
last isolate is not, they were typed by MLST. The four isolates without promoter mutations 
that were selected for cloning of the ampC gene were also included in this genotypic analysis 
to identify their founders and to examine if there are any similarities among them. A total of 
11 strains were typed. 
MLST analysis identified five different STs for these 11 strains; ST131, ST550, ST38, 
ST1291 and ST410 (presented in Figure 4.2). The six isolates that were clonally related by 
PFGE all belonged to ST131, confirming their clonal relatedness. The IS911 strain not related 
to these strains by PFGE belonged to ST550. Two of the four isolates without mutation 
alterations belonged to ST38. The last two strains belonged to ST410 and ST1291. See Table 
4.2 for results. 
 
Figure 4.2. eBURST picture of the different STs obtained from the MLST sequencing. ST types are 








Isoelectric Focusing (IEF) 
IEF was performed to establish whether the 11 selected isolates K29-48, K29-77, K29-80, 
K30-44, K33-24, K34-08, K41-39, K41-64, K44-60, K45-79, K46-23 with an AmpC 
phenotype expressed β-lactamases. The isoelectric points (pIs) were determined by 
comparison with reference β-lactamases blaTEM-1 (pI 5.4) and blaSHV-1 (pI 7.6), and naturally 
coloured IEF Protein Standards pI 4.45-9.6.  
IEF analysis revealed that all isolates expressed β-lactamases, with a pI value between 9.1 and 
9.2 corresponding to the alkaline profile of AmpC β-lactamases (Figure 4.3 and Table 4.3). 
Control strains A2-6 and A2-7 expressing blaTEM-1 and blaSHV-1, respectively, had bands at pI 
5.4 and 7.6 exclusively.  
 
 
Figure 4.3. Modified picture of the nitrocefin-stained gel with red β-lactamase bands. IEF protein 
standards pI 4.45-9.6, lane 1: K29-48, lane 2: K29-77, lane 3: K29-80, lane 4: K30-44, lane 5: K33-24, 
lane 6: K34-08, lane 7: K41-39, lane 8: K41-64, lane 9: K44-60, lane 10: K45-79, lane 11: K46-23, 

















Real-time qRT-PCR was performed to analyse the expression level of chromosomal ampC 
genes in the four isolates without alterations within the promoter and one of the isolates with 
IS911. The ampC target gene was normalized against gapA (glyceraldehyde 3-phosphate 
dehydrogenase). E. coli ATCC 25922 mean normalized expression level of mRNA was set as 
1.0, and used to calibrate the mean normalized expression levels of ampC mRNA from the 
isolates as fold differences. 
The four isolates without alterations in the promoter region had no increase in expression of 
the ampC gene, and most of them showed a slightly lower expression, compared with the 
control strain ATCC 25922. The one isolate with the IS-element IS911 showed a 60-fold 
increase of expression compared to the control (Table 4.3).  
 
 
Table 4.3. Summary of results: MLST, qRT-PCR and IEF 
 
MLST   
  Strain ST STC qRT-PCR expression pI by IEF 
IS911 isolates 
   K29-48 131 None ND 9.1 
K29-77 131 None ND 9.1 
K29-80 131 None ND 9.1 
K30-44 131 None 57.3 9.1 
K34-08 131 None  ND 9.1 
K41-39 131 None ND 9.1 
K45-79 550 ST14 ND 9.1 
Neg promoter mutation strains 
  K33-24 38 ST38 0.83 9.1 
K41-64 410 ST23 0.66 9.1 
K44-60 1291 None 0.31 9.1 









Functional characterization of ampC gene coding regions  
The functional properties of the mutated amino acid sequence of the gene coding regions in 
the four strains, K33-24, K41-64, K44-60 and K46-23, lacking promoter alterations, were 
investigated by cloning. K33-24 and K46-23 had amino acid mutations at positions 4 (M), 
201 (T) and 321 (A) differing from E. coli K12 and the sensitive isolates. It should be noted 
that one strain had the same alteration at position 4, and two strains had the same changes at 
position 201. K41-64 did not have any unique mutations differing from E. coli K12 or the 
sensitive isolates. K44-60 had one mutation in position 110 (S) as the only isolate containing 
this alteration. For the complete amino acid sequence alignment see APPENDIX 3. 
The gene coding regions were amplified without their own promoter, cloned into the plasmid 
pBK-CMV and the recombinant plasmids were transformed into the expression strain E. coli 
SNO3 [38]. E. coli ATCC 25922 (A-81) was functioning as the initially sensitive control 
strain.  
All clones were examined by antimicrobial susceptibility testing by the following Etest strips; 
ampicillin (AM), amoxicillin/clavulanic acid (XL), piperacillin (PP), piperacillin/tazobactam 
(Ptc), cefoxitin (FX), cefuroxim (XM), cefpodoxim (PX), cefotaxim (CT), 
cefotaxim/clavulanic acid (CT/CTL), ceftazidim/clavulanic acid (TZ/TZL), 
cefepime/clavulanic acid (PM/PML), aztreonam (AT), meropenem (MP) and ceftazidim. See 
Table 4.4 for results. 
 
Table 4.4. MIC (mg/L) values of β-lactams for recombinant clones with no promoter mutations         
Strain AM XL PP Ptc FX XM PX CT CT/CTL TZ/TZL PM/PML AT MP TZ 
pBKA-81 >256 64 6 6 64 32 48 2 2/>1 3.0/3.0 <0.25/<0.064 3 0.032 1.5 
pBK33-24 >256 64 12 6 >256 48 >256 3 4/>1 6.0/4.0 <0.25/<0.064 6 0.032 3 
pBK41-64 >256 96 24 6 24 16 96 3 6/>1 16.0/1.5 <0.25/<0.64 4 0.032 4 
pBK44-60 >256 64 16 6 12 12 96 3 3/>1 6.0/>4 <0.25/<0.064 4 0.032 3 
pBK46-23 >256 64 12 8 >256 96 128 3 4/>1 4.0/>4.0 <0.25/<0.064 6 0.032 3 
pBK-CMV 2 3 1 1 4 3 0.5 0.047 <0.25/0.032 <0.5/0.19 <0.25/<0.064 0.064 0.023 0.125 







5. DISCUSSION  
AmpC β-lactamases (cephalosporinases) are a clinically important group of enzymes 
produced by many Gram-negative bacteria. These enzymes are encoded on the chromosome 
of E. coli and expressed on a constitutive low basal level in their cells. When these 
cephalosporinases are overexpressed in E. coli they confer resistance to penicillins and 
cephalosporins, but not to cefpirome and cefepime.  
 
Detection of AmpC resistance determinants by sequencing 
Two main mechanisms explaining the hyperexpression of the ampC gene in 51 (92.7%) of 55 
clinical isolates were identified in this study. The first mechanism involves mutations in the 
control regions essential sites (n = 44, 79.9%) of the gene. The second mechanism revealed 
was the insertion of an IS-element IS911 (n = 7, 12.7) in the control regions of the gene.  
30 (54.5%) of the isolates with essential promoter alterations had a C→T mutation at position 
-42. Base substitution at this position is reported in many previous studies [37, 39-45] as the 
most essential alteration for hyperproduction of AmpC enzymes in E. coli. Strains possessing 
the -42 alteration usually have an additional G→A base substitution at the -18 site. In this 
study 29 (52.7%) of the strains had this mutation. Two strains were identified differing from 
this. One strain only had the substitution at position -18 while the other only had the one at 
position -42. The -42 mutation creates a new perfect TTGACA -35 box upstream of the 
normal box and in this way modifies the transcription initiation site. The -18 mutation creates 
a new -10 box with the optimal distance of 17 bp from the new -35 box. Both mutations can 
create a stronger promoter independent of each other. Studies have reported all three 
combinations of these mutations suggesting they are the most common and favoured 
promoter-region variations affecting ampC expression [41]. In this study this seems to be the 
trend as well. 
A total of seven (12.7%) strains had alterations in their -35 box changing the sequence from 
TTGTCA to TTGACA, and four (7.3%) of these also had additional mutations in the -10 box 
(TACAAT → TATAAT). The -35 box and the -10 box play an important part in the level of 




consensus sequences, the stronger the promoter will turn out to be. Both sequences are 
defined, and -35 has the consensus TTGACA whereas TATAAT is the consensus for -10. 
Several previous studies have confirmed the importance of these mutation sites in the 
promoter, indicating that the mutation in the -10 box are more rare compared to the -35 one, 
inducing moderate promoter strengths [39-41, 43-50]. 
Eight (14.5%) of the isolates had a single nucleotide insertion in the spacer region between 
the -35 box and the -10 box, resulting in an optimal 17 bp distance between them. Two of 
these strains also had the mutation TTGTCA→TTGACA in the -35 box, and two isolates had 
substitutions at position -42 and -18. The insertion mutation between the -35 and -10 boxes is 
another important property affecting the promoter strength. In the wild type E. coli the 
distance between these boxes are normally 16 bp, while the optimal distance for transcription 
is 17 bp. Mutations occurring in this spacer region changes the distance and creates a stronger 
promoter described in many previous studies [39, 40, 42, 44, 47, 50]. Previous studies imply 
that the insertion of a single nucleotide between these boxes in the ampC gene control region 
is enough to increase the expression and mediate resistance [41, 47-49].  
A total of 18 (32.7%) isolates had various mutations in their attenuator region.  Attenuator 
mutations only play a small part in increasing ampC promoter strength. All strains had 
attenuator mutations combined with other more essential mutations. See table 4.1 for details. 
Attenuator mutations are previously described in other studies [50-52].  
Seven (12.7%) isolates, K29-48, K29-77, K29-80, K30-33, K34-08, K41-39, K45-79, did not 
have any essential promoter mutations known to up-regulate the transcription of the ampC 
gene, but had an IS911 inserted between the -35 box and -10 box in the promoter region. It 
should be noted that three of the strains contained mutations in the attenuator site. Previous 
studies have described cases where the insertion of IS-elements in promoter regions can cause 
hyperproduction of the ampC gene by creating an alternative promoter. These reports include 
the IS-elements IS2, ISEc10, IS10 and IS911 [37, 41, 53]. In a previous study the IS911 
created a stronger -35 box and a 17 bp spacer region to the -10 box [50]. This will generate a 
promoter sequence looking more like the E. coli consensus promoter sequence causing 
hyperproduction of AmpC enzymes. Hyperexpression of this chromosomal ampC gene 
control region was investigated in one of the strains, K30-44, by real-time qRT-PCR. The 




correlated well with findings in Canadian studies from 2005 [41] and 2007 [50]. These seven 
isolates were examined further to investigate a possible clonal relationship between them. 
Five (9.1%) isolates had no mutations at all in their promoter regions. One of the strains, K15-
8, has been characterised in a previous Norwegian study and was identified with the IS-
element ISEc10 inserted in the promoter region, explaining the hyperproduction of AmpC 
enzymes [37]. The remaining four (7.1%) strains K33-24, K41-64, K44-60 and K46-23 had 
no obvious mutations in the gene control region to explain the observed resistance profiles 
against β-lactams. 
The IEF results showed that the seven IS911 strains K29-48, K29-77, K29-80, K30-44, K34-
08, K41-39 and K45-79 and the four isolates K33-24, K41-64, K44-60 and K46-23 without 
any mutations in the promoter, produced AmpC enzymes with pI-values 9.1 and 9.2, as 
expected. This experiment verified that strains with an AmpC phenotype actually produced 
AmpC enzymes, though this experiment is not able to quantify the level of expression or the 
AmpC enzymes hydrolytic profiles. 
 
Amino acid analysis of ampC gene coding regions 
Amino acid sequences of the ampC gene coding regions of all resistant and sensitive strains 
were aligned against E. coli K12 amino acid ampC gene coding region. The purpose was to 
identify mutations in the gene coding sequences. We focused on the four strains K33-24, 
K41-64, K44-60 and K46-23, that lacked obvious promoter or attenuator mutations or 
insertion of IS-elements that could give hyperexpression of the ampC gene. Ten sensitive 
strains were used as a control for natural sequence variations occurring in the coding region. 
The strains K33-24 and 44-60 are two of the four cefepime selected strains. These isolates had 
mutations in the gene coding sequences differing from K12 and the sensitive isolates which 
can be important for the resistance (see Table 4.2). These were selected for further sequence 
analysis (see below). 
Strain K41-64 is one of the AmpC selected strains. This isolate has no exceptional mutations 
compared to K12 or in the gene coding sequence that can explain the decreased susceptibility 




Strain K46-23 is one of the AmpC selected strains. This isolate has mutations in the gene 
coding sequence differing from K12 and the sensitive isolates which can be important for the 
resistance (see Table 4.2). This strain was selected for further sequence analysis (see below). 
These 4 strains were selected for further studies, to examine if the alterations in their gene 
coding region enhance their ability to hydrolyse broad-spectrum and extended-spectrum 
cephalosporins (see below). 
Mutations in the ampC coding sequence can modify the enzymes structure and in that way 
broaden their substrate profiles. Previous studies performed by Mammeri et al have found 
several mechanism of resistance producing cephalosporinases with broadened substrate 
activity, expanded-spectrum AmpC (ESAC) β-lactamases. These mechanisms involved amino 
acid insertions [54, 55] and substitutions [56] of the ampC gene coding sequence altering their 
enzymes structure and resistance profiles. 
The expression of the chromosomal ampC genes in the strains without promoter mutations or 
insertions was investigated by real-time qRT-PCR. And the results revealed no increased 
expression compared with E. coli ATCC 25922. These results did not unveil any surprises 
knowing only isolates with control region mutations hyperexpress ampC. This confirms that 
other factors are involved contributing to these strains resistance profiles against 
cephalosporins.  
MLST analysis results showed that two of the isolates without promoter mutations, K33-24 
and K46-23, was identified as ST38 belonging to ST complex 38. One strain, K41-64, was 
identified relating to ST complex 23 as ST410. And the strain K44-60 was identified relating 
to ST complex 10 as ST1291. STC38 related strains are globally distributed uropathogenic 
and enteroaggregative E. coli isolates from Brazil, Germany, India and Nigeria. Japan 
recently identified ST38 strains in CTX-M producing isolates [57], and a Norwegian study 
recently reported CMY-2 producing multidrug resistant isolates related to STC 38 [58]. 
 
Functional characterisation of the ampC gene coding regions 
This study of the functional characterisation of the ampC gene coding sequence was 
interesting, because a recent study on E. coli isolates conferring reduced susceptibility to all 




mechanism, involving structural modifications in designated regions of the cephalosporinase 
sequence [45]. The functional properties of the ampC gene in the four strains K33-24, K41-
64, K44-60 and K46-23 were investigated to establish whether mutations in the amino acid 
sequences reduce their susceptibility to cephalosporins or broaden their substrate activity. The 
cloned ampC gene coding region from E. coli ATCC 25922 (A-81) functioned as the 
susceptible control. The empty pBK-CMV vector transformed into SNO3 and SNO3 without 
any plasmid functioned as controls without any expressed AmpC enzymes. The four selected 
strains gene coding regions were cloned into the high copy vector pBK-CMV followed by 
expression in E. coli SNO3 [38]. The MIC values for selected β-lactam antibiotics were 
determined with a panel of Etests to establish the resistance profiles for all clones and 
controls. From this point the selected strains will be discussed separately based on their initial 
selection criteria for this study. K33-24 and K44-60 were chosen based on their decreased 
susceptibility to cefepime without clavulanic acid synergy, not fulfilling the AmpC selection 
criteria. K41-64 and K46-23 were chosen based on their AmpC phenotype profile showing 
decreased susceptibility to cefotaxime and ceftazidime without clavulanic acid synergy. 
E. coli ATCC 25922 is susceptible to cephalosporins. When its gene was cloned into a high 
copy vector expressing and producing AmpC enzymes on a high level in SNO3, this strain 
had decreased susceptibility towards penicillins and cephalosporin antibiotics. In Table 4.3 
where the MIC values are listed we see that SNO3 pBKA-81 is resistant to penicillins and 
cephalosporins, but were still susceptible to meropenem (MP).  
Both pBK-CMV and SNO3 are completely susceptible towards all the β-lactam panels in this 
test, confirming they do not have any AmpC production in their cells.  
Comparing pBK33-24 and pBK44-60 to pBKA-81 there is not a significant difference for any 
of the β-lactams tested. pBK44-60 has more or less identical MIC values compared to pBKA-
81. pBK33-24 is expressing somewhat higher MIC values for cefoxitin and cefpodoxime 
compared to pBKA-81 and pBK44-60. Since these strains were cefepime selected one could 
expect an increased cefepime/clavulanic acid MIC compared to pBKA-81, but this was not 
observed. This suggests that the elevated resistance for cefepime in these isolates could be due 
to a porin mutation leading to a decrease in permeability in the outer membrane, rather than 




pBK41-64 and pBK46-23 did not either express any higher MIC values compared to pBKA-
81. pBK41-64 has almost identical values as the control for most of the β-lactams. pK46-23 is 
expressing higher MIC values for cefoxitin and cefpodoxime, like pBK33-24, compared to 
pBKA-81 and pBK41-64. We also expected to see an increase for the cefepime/clavulanic 
acid MICs in these strains as well, but there were no change in the catalytic efficacy in these 
either. When it comes to these two strains we have no good answers to why they have a 
typical AmpC phenotype resistance profile, because this study suggest that the gene coding 
mutations have nothing to say for the catalytic efficacy. A possible explanation for these 
strains can be that they possess a plasmid-mediated ampC gene that the multiplex PCR are 
unable to detect, like the ACC-1 β-lactamase. We cannot exclude that these enzymes have 
higher catalytic efficiencies against typical substrates for AmpC enzymes, but that such subtle 
differences are masked by the high expression of the genes from a high copy vector. 
 
Genotypic studies of isolates with the IS-element IS911  
PFGE analysis revealed that six of the seven IS911 isolates were clonally related to each 
other. Further epidemiological data for these seven strains were collected. The six isolates 
K29-48, K29-77, K29-80, K30-44, K34-08 and K41-39 were all collected from patients in 
different institutions from the same area in Bergen. The seventh isolate K45-79 was collected 
from a patient in a hospital in Vestfold. Further patient data revealed that three, K29-77, K29-
80, K30-44, of the six related strains were isolated from the same patient with one month 
between each isolation. This patient’s first isolate K29-77 was isolated in the hospital in 
January 2006, the second isolate K29-80 was isolated in the nursing home in February 2006, 
and the third isolate K30-44 was isolated in a new nursing home in March 2006. The three 
other isolates were collected from different patients in the same nursing home. The first strain 
K29-48 was isolated in December 2005, the second strain K34-08 was isolated in August 
2006, and the third strain K41-39 was isolated in March 2007. The most likely link between 
these clonal strains is a medical centre both nursing home use. The clonal outbreak of this E. 
coli clone probably started in December 2005 when the first strain was isolated in this medical 
centre. This is, to our knowledge, the first clonal outbreak of an E. coli with the IS911 




The clonal relationship between the four strains, carrying IS911 in their promoter region, was 
confirmed with MLST typing identifying all isolates as ST131. The isolate from Vestfold was 
identified as ST550 belonging to ST complex 14.  
Previous studies of MLST sequence types in clinical E. coli have identified that strains of 
ST131 are globally disseminated presenting successful, often highly virulent and resistant 
clone lineages. ST131 strains are associated with the global dissemination of CTX-M-15 type 
ESBL [15, 59], extended spectrum cephalosporin-resistance and plasmid-mediated quinolone 
resistance in the UK [60, 61], ciprofloxacin-resistance in eight European countries [62, 63], 
and with CMY-2 producing isolates in Norway [58]. They have also been isolated from stool 
samples of healthy people [64] and of cats and dogs within households [65]. One recent report 
describes the transmission of an ST131 E. coli between a father and daughter causing serious 
illness [66].  
 
Concluding remarks 
Results from the characterising of the gene control regions confirmed that the most usual 
mechanisms of resistance in these strains are mutations in the important and already known 
mutation sites in this region. These mutations increase the level of mRNAs and hence AmpC 
enzymes in the cells making them more resistant. Those isolates not having promoter 
mutations did not hyperexpress AmpC on mRNA level, suggesting other mechanisms 
responsible for their resistance. 
The characterising of the gene coding regions gave us two different explanations. The cloned 
cefepime selected ampC genes had no change in the β-lactam MICs compared to the sensitive 
clone suggesting porin mutations making the cell more impermeable as a mechanism for their 
resistance against cefepime. The cloned AmpC selected ampC genes had no change either in 
the β-lactam MICs compared to the sensitive clone. This result leaves us with no reason for 
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APPENDIX 1. Complete Etest for all clinical and sensitive strains 
Strain number Ampicillin Amoxy/clav Piperacillin Pip/tazo Cefoxitin Cefuroxim Cefpodoxim Cefotaxim Cefotax/clav Ceftazidime Cefta/clav Cefepim/clav Aztreonam Imipenem Meropenem Cefox/boronic
K2-68 256 24 192 12 64 ND 96 4 4/>1 16 16/>4 <0,25 3 0.25 0.016 ND
K4-30 >256 48 24 24 256 ND 256 6 8/>1 16 24/>4 0,5 4 0.5 0.023 ND
K4-37 >256 32 64 24 96 ND 64 4 4/>1 12 16/>4 0,38 6 0.25 0.023 ND
K8-02 >256 24 32 24 >256 ND 256 16 16/>1 12 12/>4 0,25 16 0.19 0.023 ND
K9-38 >256 32 24 16 64 ND 64 6 6/>1 8 8/>4 <0,25 4 0.25 0.016 ND
K9-66 >256 48 12 12 256 ND 192 6 12/>1 16 16/>4 <0,25 4 0.25 0.023 ND
K14-27 >256 32 32 24 256 ND 128 6 12/>1 24 32/>4 0,38 6 0.25 0.016 ND
K14-35 >256 96 96 64 >256 ND >256 32 >16/>1 64 32/>4 1,5 16 0.75 0.032 ND
K15-08 >256 32 32 32 128 ND 64 3 4/0.5 16 24/>4 0,38 12 0.25 0.023 ND
K22-31 >256 24 16 6 192 ND 128 4 4/>1 24 16/>4 <0,25 6 0.19 0.016 ND
K25-19 >256 48 24 8 256 ND >256 6 8/>1 16 16/>4 <0,25 6 0.25 0.023 ND
K25-65 >256 48 6 4 128 ND >256 12 16/>1 12 12/>4 3 6 0.19 0.023 ND
K29-48 > 256 64 32 6 128 ND 48 4 2 / > 1 6 6 / > 4 < 0,25 / 0,094 4 0,38 0,032 ND
K29-77 > 256 32 32 8 256 ND 96 4 3 / > 1 6 6 / > 4 < 0,25 / 0,125 8 0,38 0,023 Pos
K29-80 > 256 32 32 8 256 ND 64 4 3 / > 1 8 6 / > 4 < 0,25 / 0,094 6 0,25 0,023 Pos
K30-01 > 256 48 24 12 128 ND 256 4 6 / > 1 48 > 32 / > 4 < 0,25 / 0,19 4 0,19 0,016 Pos
K30-18 > 256 32 12 4 64 ND 128 4 3 / > 1 12 12 / > 4 < 0,25 / 0,064 12 0,25 0,023 Pos
K30-39 > 256 96 48 24 > 256 ND 256 8 4 / > 1 24 24 / > 4 0,25 / 0,19 16 0,75 0,094 Pos
K30-44 > 256 24 32 6 192 ND 48 3 2 / >1 6 3 / 4 3 / 4 6 0,19 0,023 Pos
K30-45 > 256 32 16 6 192 ND 64 4 3 / > 1 8 8 / >4 < 0,25 / 0,125 8 0,19 0,023 Pos
K33-01 > 256 32 > 256 12 128 ND 64 4 4 / > 1 12 8 / > 4 < 0,25 / 0,125 8 0,25 0,016 Pos
K33-03 > 256 24 > 256 2 32 ND > 256 > 256 > 16 / 0,5 24 24 / 0,5 > 16 fant / < 0,064 48 0,25 0,023 Pos
K33-24 > 256 16 > 256 12 256 ND 8 3 1,5 / > 1 2 1,5 / 0,5 1,5 / 0,38 1,5 0,19 0,023 Pos
K33-54 > 256 32 > 256 24 256 ND 128 4 3 / > 1 12 8 / > 4 0,25 / 0,094 8 0,25 0,032 Pos
K34-08 > 256 64 48 12 192 48 64 4 3 / > 1 ND 4 / 4 < 0,25 / 0,094 6 0,38 0,032 Pos
K34-10 > 256 48 16 12 128 64 64 4 3 / 1 ND 8 / 2 < 0,25 / 0,125 6 0,38 0,023 Pos
K34-32 > 256 48 32 24 > 256 128 96 4 4 / > 1 ND 8 / 2 < 0,25 / 0,094 8 0,38 0,094 Pos
K34-43 > 256 48 32 12 256 128 128 8 8 / > 1 ND 24 / > 4 0,38 / 0,38 8 0,38 0,19 Pos
K34-61 > 256 128 32 24 256 96 96 6 6 / > 1 ND 32 / > 4 < 0,25 / 0,125 16 1 0,19 Pos
K34-69 > 256 32 > 256 > 256 96 256 64 4 4 / > 1 ND 6 / 2 < 0,25 / 0,094 8 0,25 0,032 Pos
K34-76 > 256 32 24 8 64 32 64 6 4 / > 1 ND 8 / > 4 0,75 / 0,5 2 0,19 0,094 Pos
K36-13 > 256 48 48 24 192 128 256 6 8 / > 1 ND > 32 / > 4 0,38 / 0,125 12 0,25 0,047 Pos
K36-22 > 256 48 24 6 128 > 256 64 4 3 / > 1 ND 6 / 4 < 0,25 / 0,094 12 0,19 0,047 Pos
K36-30 > 256 48 12 6 32 64 64 4 3 / > 1 ND 8 / > 4 < 0,25 / 0,094 6 0,19 0,047 Pos
K36-50 > 256 48 24 8 48 64 96 4 3 / > 1 16 ND < 0,25 / 0,094 8 0,25 0,032 Pos
K41-19 > 256 32 24 8 64 48 64 4 4 / > 1 ND 16 / 2 < 0,25 / 0,19 6 0,25 0,047 Pos
K41-22 > 256 32 24 12 96 96 96 6 3 / > 1 ND 16 / 4 < 0,25 / 0,125 12 0,25 0,023 Pos
K41-34 > 256 32 96 12 192 > 256 64 4 2 / > 1 ND 6 / 2 < 0,25 / 0,125 16 0,25 0,047 Pos
K41-39 > 256 32 64 8 256 64 64 4 3 / > 1 ND 6 / 2 < 0,25 / 0,125 6 0,25 0,032 Pos
K41-52 > 256 32 24 8 96 96 64 4 2 / > 1 8 6 / 1,5 < 0,25 / 0,125 4 ND 0,023 Pos
K41-53 > 256 24 16 8 256 256 96 4 2 / > 1 16 12 / 4 0,25 / 0,125 8 ND 0,012 Pos
K41-64 > 256 32 128 16 96 > 256 > 256 48 > 16 / > 1 128 > 32 / > 4 0,5 / 0,38 12 ND 0,023 Pos
K41-71 > 256 48 > 256 12 > 256 48 48 4 2  / > 1 4 2 / 1,5 0,38 / 0,19 6 ND 0,094 Pos
K44-58 > 256 24 32 24 192 96 64 4 4 / > 1 6 4 / 0,5 < 0,25 / < 0,064 8 ND 0,012 Pos
K44-60 > 256 8 96 8 96 64 6 2 1 / 0,25 3 2 / 0,25 1 / 0,19 0,75 ND 0,023 Pos
K44-72 48 8 8 8 256 > 256 12 2 1,5 / > 1 2 1 / 0,19 1 / 0,094 1,5 ND 0,016 Pos
K44-77 > 256 24 32 12 96 128 128 4 6 / > 1 16 12 / 2 < 0,25 / < 0,064 8 ND 0,023 Pos
K45-79 > 256 24 32 24 128 96 64 4 4 / > 1  8 6 / >4 < 0,25 / < 0,064 4 ND 0,016 Pos
K46-03 > 256 32 > 256 8 96 64 64 4 4 / > 1 16 8 / > 4 < 0,25 / 0,094 6 ND 0,023 Pos
K46-23 > 256 24 48 1,5 96 > 256 > 256 32 > 16 / > 1 48 > 32 / > 4 0,38 / 0,25 8 ND 0,032 Pos
K46-34 > 256 32 96 24 64 96 96 6 8 / > 1 12 8 / > 4 < 0,25 / 0,125 12 ND 0,023 Pos
K46-40 > 256 16 48 12 > 256 256 256 8 8 / > 1 8 6 / 4 < 0,25 / < 0,064 12 ND 0,023 Pos
K46-46 > 256  48 256 64 > 256 > 256 > 256 24 > 16 / > 1 128 > 32 / > 4 0,38 / 0,38 128 ND 0,25 Pos
K46-48 > 256 32 16 4 128 48 48 4 3 / > 1 8 4 / 1,5 < 0,25 / < 0,094 6 ND 0,047 Pos
K46-52 > 256 32 48 8 64 48 96 4 3 / > 1 12 8 / 4 < 0,25 / 0,125 4 ND 0,047 Pos
K46-73 > 256 16 256 48 > 256 > 256 256 8 16 / > 1 48 < 0,25 / 0,094 16 ND 0,023 Pos
Sensitive stammer!
K18-03 >256 16 >256 3 4 ND 64 12 16/0.094 1 0.75/0.19 3/>0.064 2 0.19 0.023 ND
K27-39 ≥32 16 ND ≤4 8 ND 1 ≤1 ND ≤1 ND ND ≤1 ND ≤0.25 ND
K27-41 ≥32 4 ND ≤4 ≤4 ND ≤0.25 ≤1 ND ≤1 ND ND ≤1 ND ≤0.25 ND
K27-42 ≥32 4 ND ≤4 8 ND 0.5 ≤1 ND ≤1 ND ND ≤1 ND ≤0.25 ND
K27-43 4 ≤2 ND ≤4 ≤4 ND 0.5 ≤1 ND ≤1 ND ND ≤1 ND ≤0.25 ND
K27-44 8 4 ND ≤4 8 ND 2 ≤1 ND ≤1 ND ND ≤1 ND ≤0.25 ND
K27-45 4 4 ND ≤4 ≤4 ND ≤0.25 ≤1 ND ≤1 ND ND ≤1 ND ≤0.25 ND
K27-46 8 4 ND ≤4 8 ND 1 ≤1 ND ≤1 ND ND ≤1 ND ≤0.25 ND
K27-47 8 ≤2 ND ≤4 ≤4 ND 0.5 ≤1 ND ≤1 ND ND ≤1 ND ≤0.25 ND
ATCC 25922 4 ≤2 ND ≤4 ≤4 ND ≤0.25 ≤1 ND ≤1 ND ND ≤1 ND ≤0.25 ND
APPENDIX 2. Nucleotide alignment of ampC promoter sequences.    
 
   ------------------+-------------------+-------------------+-------------------+-------------------+-------------------+-------------------+-------------------+----------- 
                        10                  20                  30                  40                  50                  60                  70                  80           
      ------------------+-------------------+-------------------+-------------------+-------------------+-------------------+-------------------+-------------------+----------- 
   1  T G C A C G A T C T G A A A A T C C A C G T A C C T G C G G G C A A A T G G G T T T T C T A C G G T C T G G C T G C T A T C C T G A C A G T T G T C A C G C T G A T T G G  E.coli K-12 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K2-68 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K4-30 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K4-37 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  K8-2 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K9-38 
   1  . . . . . . . . . . . . . G . . T . . . . . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K9-66 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K14-27 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K14-35 
   1  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - N N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  K15-8 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K22-31 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K25-19 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K25-65 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K29-48 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K29-77 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K29-80 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K30-1 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K30-18 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K30-39 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K30-44 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K30-45 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K33-1 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  K33-24 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . A . . . . . . . .  K33-3 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . .  K33-54 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K34-10 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K34-32 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K34-43 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K34-61 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K34-69 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K34-76 
   1  . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K34-8 
   1  . . . . . . . . . . . . . G . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K36-13 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K36-22 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K36-30 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K36-50 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K41-19 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  K41-22 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . A . . . . . . . .  K41-34 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K41-39 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K41-52 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K41-53 
   1  . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  K41-64 
   1  . . . . . . . . . . . . . - . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K41-71 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . .  K44-58 
   1  . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  K44-60 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  K44-72 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K44-77 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . .  K45-79 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K46-03 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  K46-23 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K46-34 
   1  . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . .  K46-40 
   1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . .  K46-46 
   1  . . . . . . . C . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K46-48 
   1  . . . . . . . . . . . . . . . . T . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . .  K46-52 







      --------+-------------------+-------------------+-------------------+-------------------+-------------------+-------------------+-------------------+------------------- 
              90                  100                 110                 120                 130                 140                 150                 160                  
      --------+-------------------+-------------------+-------------------+-------------------+-------------------+-------------------+-------------------+------------------- 
  86  T G T C G T - T - A C A A T C T A A C G C A T C G C C A A T G T A A A T C C G G C C C G - C C T A T G G C G G G C C G T T T T G T A T G G A A A C C A G A C C C T A T G    E.coli K-12 
  86  . A . . . . - . - . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . .    K2-68 
  86  . A . . . . - . - . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . .    K4-30 
  86  . A . . . . - . - . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . .    K4-37 
  86  . . . . . . T . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . - . . G T . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    K8-2 
  86  . A . . . . - . - . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . T . . . .    K9-38 
  86  . A . . . . - . - . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . .    K9-66 
  86  . A . . . . - . - . . . . . . . . . . . T . . . . A . . . . . . . . . . . . . . . . . . - . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . T . . . .    K14-27 
  86  . A . . . . - . - . . . . . . . . . . . T . . . . A . . . . . . . . . . . . . . . . . . - . . . . . . . . A . . . . . . . . . . . . . . . . G . . . . . . . . T . . . .    K14-35 
  36  . . . . . . - . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    K15-8 
  86  . A . . . . - . - . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . .    K22-31 
  86  . A . . . . - . - . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . .    K25-19 
  86  . . . . C G - . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . - A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    K25-65 
  86  . . . . - G - . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    K29-48 
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APPENDIX 3: Amino acid alignment of the complete ampC gene coding region for E. coli K-12, cephalosporin resistant and sensitive (grey) strains. Amino acids that differ from E. coli K-12   
are shown. 
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